

Bobby Jindal
GOVERNOR



Bruce D. Greenstein
SECRETARY

State of Louisiana
Department of Health and Hospitals
Office of the Secretary

March 18, 2011

The Honorable Bobby Jindal
Governor, State of Louisiana
P.O. Box 94004, Capitol Station
Baton Rouge, LA 70804-4004

The Honorable Joel T. Chaisson, II, President
Louisiana State Senate
P.O. Box 94183, Capitol Station
Baton Rouge, LA 70804-9183

The Honorable Jim Tucker, Speaker
Louisiana State House of Representatives
P.O. Box 94062, Capitol Station
Baton Rouge, LA 70804-9062

Dear Governor Jindal, President Chaisson, and Speaker Tucker:

In response to Senate Bill No. 689 of the 2004 Regular Session and House Bill No. 369 of the 2005 Regular Session, the Louisiana Department of Health and Hospitals (DHH) submits the enclosed report. These bills require DHH to provide an annual written report to the governor and to the legislature regarding the cost of administering the preferred drug list, including the cost of administering the prior authorization function, the costs of development and maintenance of the preferred drug list and aggregate funds returned to the federal government related to pharmaceutical rebates, and an analysis of the utilization trends for medical services provided by the state and any correlation to the preferred drug list. R.S. 24:772 also requires that the report be submitted to the President of the Senate and the Speaker of the House.

The bureau of health services financing (Medicaid) within DHH is available to discuss the enclosed report and recommendations with you at your convenience. Please contact M.J. Terrebonne, pharmacy director, at (225) 342-9768 with any questions or comments you may have.

Sincerely,

A handwritten signature in black ink, appearing to read "B. D." followed by a stylized surname. Below the signature, the name "Bruce D. Greenstein" and the title "Secretary" are printed in a smaller font.

Enclosures

Cc: Senator Lydia Jackson
Senator Willie L. Mount
Representative Kay Katz
David R. Poynter Legislative Research Library

DEPARTMENT OF HEALTH AND HOSPITALS

PREFERRED DRUG LIST (PDL)

REPORT PREPARED IN RESPONSE TO -
SENATE BILL NO. 689 (ACT 705) OF THE 2004
REGULAR SESSION AND HOUSE BILL NO.
369 (ACT 177) OF THE 2005 REGULAR
SESSION

MARCH 2011

Contact:

Louisiana Department of Health and Hospitals

M. J. Terrebonne

Bureau of Health Services Financing

628 North Fourth Street – 7th Floor, Baton Rouge, LA 70802

(225) 342-9768

MJTERREBONNE@LA.GOV

EXECUTIVE SUMMARY

Act 395 of the 2001 Regular Session of the Louisiana Legislature amended R.S.46:153.3 (B)(2)(a) and authorized the Department of Health and Hospitals (DHH) to establish a drug formulary utilizing a prior approval process or any other process or combination of processes that prove to be cost-effective in the medical assistance program. The Act also created a Pharmaceutical and Therapeutics Committee consisting of 21 members appointed by the Governor. The list of members can be found at www.legis.state.la.us/boards/boardsearch.asp.

The Committee began meeting in August 2001. On June 10, 2002, the Department implemented a preferred drug list (PDL) with a prior authorization (PA) process and a Supplemental Drug Rebate program through a phased-in approach. The PDL/PA process and accompanying supplemental rebate features were implemented meeting all applicable federal and state statutes.

Subsequently, Senate Bill No. 689 (Act 705) of the 2004 Regular Session of the Louisiana Legislature provides each year the department shall provide a written and public report to the legislature and the governor thirty days prior to the regular legislative session. The report shall cover: (i) The cost of administering the preferred drug list, including the cost of administering the prior authorization function, the costs of development and maintenance of the preferred drug list and aggregate funds, returned to the federal government related to pharmaceutical rebates; and (ii) An analysis of the utilization trends for medical services provided by the state and any correlation to the preferred drug list (*Appendix 1*).

Act 177 of the 2005 Regular Session further amended the PDL/PA process. R.S.46:153.3(C) added atypical antipsychotic drug class and the immunomodulator and hepatitis C – specific antiviral drug class and required DHH to include data from these classes with the data collected on all drug classes reviewed on the Medicaid PDL for the annual report to the Legislature and Governor (*Appendix 2*).

The program is administered by the Medicaid Pharmacy Benefits Management section of DHH utilizing the services of three contractors: Molina (formerly Unisys; the University of Louisiana at Monroe (ULM), School of Pharmacy; and Provider Synergies. The PDL/PA process and supplemental rebate system are now fully operational.

Each prior authorization is given for a specific drug for a specific recipient for a specific period of time. In accordance with state and federal statutes, requests must be acted upon within 24 hours. Also, a minimum of a 72-hour supply of a medication may be obtained without prior authorization in emergency situations.

In SFY 2010, ULM processed approximately an average 17,079 prior authorization requests monthly. Listings of those drugs which receive prior authorization requests are included in the Preferred Drug List (PDL)/Prior Authorization (PA) list at www.lamedicaid.com and *Appendix 3* of this report.

The state received \$45,635,734 in supplemental rebates in SFY 2009 and approximately \$42,740,235 in SFY 2010. The last quarter of SFY supplemental rebates were impacted by the Patient Protection and Affordable Care Act (PPACA), P.L. 111-148, and the Health Care and Education Reconciliation Act of 2010 (HCERA), P.L. 111-152, which were enacted on March 30, 2010. Section 2501 of PPACA and section 1206 of HCERA include changes to certain Medicaid drug rebate provisions, effective first quarter

2010. Several of these changes impact the Unit Rebate Amount (URA) calculation for all drugs covered under the Medicaid Drug Rebate Program. As a result of this legislation Provider Synergies has not provided projections for program savings for SFY 2011 resulting from market shift and supplemental rebates. More detailed information regarding the PDL, Federal legislation and the financial methodology is available in the body of the report and in the *Louisiana Medicaid PDL Program Overview and Results, February 1, 2011* report available at <http://www.dhh.louisiana.gov/offices/publications.asp?ID=134&Detail=3373>.

The foregoing is presented as a brief overview. The following is the report with appropriate appendices.

MEDICAID PHARMACY BENEFITS MANAGEMENT PROGRAM

Background

Prior to 2001 Louisiana had an open formulary law which required Medicaid reimbursement of all FDA approved legend drugs, with a few exemptions. The law also prohibited the use of prior or post-authorizations in the pharmacy program. These laws restricted Louisiana's use of management tools available to other states to control costs.

Act 395 of the 2001 Regular Session of the Louisiana Legislature amended R.S.46:153.3 (B)(2)(a) and eliminated the prohibition of utilizing a prescription prior authorization process within the Louisiana Medicaid Program. The law authorizes the Department of Health and Hospitals (DHH) to "...establish a drug formulary that utilizes a prior approval process or any other process or combination of processes that prove to be cost-effective in the medical assistance program...."

Other provisions of Act 395 and R.S. 46:153.3 are:

- Permits DHH to enter into contractual arrangements to perform the prior approval (PA) functions with a school of medicine, a college of pharmacy, the fiscal intermediary for the Medicaid program, or such other qualified contractors that it deems appropriate, within the scope of the PA mandated provisions of federal law.
- Mandates a maximum 24-hour response time on requests.
- Requires that a 72-hour supply of a medication may be obtained without a prior authorization in emergency situations.
- Creates a Pharmaceutical and Therapeutics Committee comprised of 21 members who are appointed by the Governor and confirmed by the Senate. The list of members can be found at www.legis.state.la.us/boards/boardsearch.asp (Medicaid and Pharmaceutical and Therapeutics Committee).

Subsequently, Senate Bill No. 689 (Act No. 705) of the 2004 Regular Session was passed requesting additional information be reported to the Legislature and the Governor 30 days prior to the regular legislative session (*Appendix 1*). Specifically, the report shall cover: 1) The cost of administering the preferred drug list, including the cost of administering the prior authorization function, the costs of development and maintenance of the preferred drug list and aggregate funds, returned to the federal government related to pharmaceutical rebates; and 2) An analysis of the utilization trends for medical services provided by the state and any correlation to the PDL.

Act 177 (HB 369) of the 2005 Regular Session and Act 107 (HB 680) of the 2007 Regular Session further amended the PDL/PA process (*Appendix 2*). R.S.46:153.3(C) added atypical antipsychotic drug class and the immunomodulator and hepatitis C – specific antiviral drug class and required DHH to include data from these classes with the data collected on all drug classes reviewed on the Medicaid preferred drug list for the annual report to the legislature and governor.

Program Implementation and Operations

On June 10, 2002 DHH implemented a PDL with a PA process and a Supplemental Drug Rebate program through a phased-in approach. The PDL/PA process and accompanying supplemental rebate feature were implemented meeting all applicable federal and state statutes.

The program is administered by the Medicaid Pharmacy Benefits Management section of DHH and utilizes the services of three contractors: Molina (formerly Unisys); the University of Louisiana at Monroe (ULM), School of Pharmacy; and Provider Synergies. Services provided by the contractors include:

- Molina (formerly Unisys), the Medicaid fiscal intermediary
 - Technology equipment purchase/installation (with ULM) to support the program
 - Application modifications to the current Medicaid Management Information System (MMIS)
 - Design and implement Wide Area Network (WAN) for ULM
 - Creation and support of new web-based pharmacy PA software
 - Implementation of data research applications
 - Design, install and support a data warehouse
 - SAS training for ULM research analysts
 - Training on Pharmacy PA System (DHH and ULM staff)
 - Training prescribers and providers on the PA process
 - Maintain and support PDL/PA and supplemental rebate systems and operations
- University of Louisiana at Monroe (ULM) School of Pharmacy
 - Provide space, staff, and computers
 - Operate pharmacist-staffed PA desk
 - Provide physician consultations
 - Serve as consultants on the Preferred Drug List and Prior Authorization program
 - Perform DHH directed data analysis and outcome studies
- Provider Synergies
 - Secure clinical and costing data for drugs in selected therapeutic classes
 - Perform clinical and economic analysis of manufacturer data
 - Negotiate state supplemental rebates with manufacturers
 - Prepare therapeutic class monographs for Pharmaceutical and Therapeutics Committee deliberations
 - Present clinical and costing data to the Pharmaceutical and Therapeutics Committee

The PDL/PA process and supplemental rebate system are now fully operational. Each prior authorization is given for a specific drug for a specific recipient for a specific period of time. In accordance with state and federal statutes, requests must be acted upon within 24 hours. Also, a minimum of a 72-hour supply of a medication may be obtained without prior authorization in emergency situations.

Under the provisions of R.S.46:153.3 (D), the Louisiana Medicaid Pharmaceutical and Therapeutics Committee was established and began meeting in August 2001. The Committee, comprised of 21

members, including physicians and pharmacists, has met quarterly and is responsible for developing the preferred drug list (PDL) in conjunction with the PA process. The Committee reviews clinical and cost data on various therapeutic classes of drugs for recommendation to DHH for inclusion on the PDL or for review through the prior authorization process.

The PDL is updated bi-annually upon DHH's approval of the Committee's recommendations. The PDL is mailed to prescribers and pharmacists quarterly and is also available on the web at www.lamedicaid.com.

PDL/PA and Supplemental Rebate Impact

The Louisiana DHH contracts with Provider Synergies to negotiate state supplemental rebates with drug manufacturers for the state. Based on these negotiations the state received \$45,635,734 in supplemental rebates in SFY 2009 and \$42,740,235 in SFY 2010. More detailed information is available in Table 1.1.

Savings for the first three quarters of FY 2010 were approximately \$38.6 million. At this time it is not possible to finalize total year end savings for FY2010. As mentioned previously, Federal legislation was implemented changing how rebates are calculated. The Patient Protection and Affordable Care Act (PPACA), P.L. 111-148, and the Health Care and Education Reconciliation Act of 2010 (HCERA), P.L. 111-152, were enacted on March 30, 2010. Section 2501 of PPACA and section 1206 of HCERA include changes to certain Medicaid drug rebate provisions, effective first quarter 2010. Several of these changes impact the Unit Rebate Amount (URA) calculation for all drugs covered under the Medicaid Drug Rebate Program.

Provisions of this Statute increased rebate percentages for covered outpatient drugs (from 15% to 23.1% of the Average Manufacturer Price for brand name products and from 11% to 13% of the Average Manufacturer Price for generic drugs), dispensed to Medicaid patients and established the rebate offset associated with the increase in the rebate percentages. Under the previous statute, states sent the Federal government a portion equal to the share of Medicaid funding the federal government paid. Under the new law, the federal government keeps 100 percent of the rebate, the offset, that falls within the previous range to the new statutory level. Any rebates above 23.1% will continue to be shared.

Currently, CMS is enhancing their systems to accommodate these changes. As a result, unit rebate amounts of zeroes have been submitted to states for invoicing while drug manufacturers are required to calculate their unit rebate amounts and remit their payment in accordance with the ACA. This means that states are collecting the increased rebate amounts which are due on behalf of the Federal government.

In the September 28, 2010 CMS letter (SMDL#10-019), states were issued guidance on the federal government's in calculating their estimated "offset" amounts. CMS will determine the "offset" amount on a quarterly basis for the states and it will be populated on the CMS-64.

CMS has created a phased in process for the offset amounts until August 2011 when the quarterly rebate offset amounts will be available for the current quarter along with the reconciliation of the prior quarters back to January 1, 2010.

More detailed information regarding the PDL, Federal legislation and the financial methodology is available in the *2011 Legislative Report on SB 689 and HB369* at <http://www.dhh.louisiana.gov/offices/publications.asp?ID=134&Detail=3373>.

Table 1.1
PDL/PA AND SUPPLEMENTAL REBATE PROGRAM SAVINGS

PROGRAM SAVINGS		
SFY 2009	SFY 2010	SFY 2011
\$37,316,515	\$38,625,704*	\$0**
SUPPLEMENTAL REBATE		
SFY 2009	SFY 2010	SFY 2011***
\$45,635,734	\$42,740,235	\$20,897,388
FEDERAL		
71.60%	68.53%	64.61%
\$32,675,186	\$29,289,883	\$13,501,802
STATE		
28.40%	31.47%	35.39%
\$12,960,548	\$13,450,352	\$7,395,586

* Savings for the first three quarters of FY 2010. Fourth quarter not reported due to changes as a result of the Patient Protection and Affordable Care Act (PPACA), P.L. 111-148, and the Health Care and Education Reconciliation Act of 2010 (HCERA), P.L. 111-152, which were enacted on March 30, 2010.

** Savings will be realized, however projections could not provided due to zeroes reported as a result of the Patient Protection and Affordable Care Act (PPACA), P.L. 111-148, and the Health Care and Education Reconciliation Act of 2010 (HCERA), P.L. 111-152, which were enacted on March 30, 2010.

***YTD (7/1/2010 – 12/31/2010)

Cost of Prior Authorization (PA) Operations

The Medicaid Pharmacy Benefits Management program utilizes the services of the University of Louisiana at Monroe (ULM) School of Pharmacy, and Provider Synergies for PA operations. Costs for the contractors' services are found in *Table 1.2*.

ULM receives and processes all requests. Listings of those drugs which receive prior authorization requests are available at www.lamedicaid.com and included in *Appendix 3* of this report. Each prior authorization is given for a specific drug for a specific recipient for a specific period of time. In accordance with state and federal statutes, requests must be acted upon within 24 hours. Provisions are in place whereby an emergency override is allowed for a minimum of a 72-hour supply of medicine. During the most recent two quarters the program has averaged approximately 1,242 emergency overrides. Detailed Emergency Override Report is in *Table 1.3*. ULM processed approximately 204,951 prior authorization transactions in SFY 2010 and approximately 121,019 in SFY 2011 (as of 12/31/10).

Table 1.2
PDL/PA AND SUPPLEMENTAL REBATE CONTRACT COSTS

		2010		
		Cost	Federal Share	State Share
		50%	50%	
Molina (formerly Unisys)	Pharmacy (PA)	\$605,296	\$302,648	\$302,648
Provider Synergies	Baseline costs	\$649,992	\$324,996	\$324,996
DHH	15% of salaries	\$139,701	\$69,850	\$69,850
ULM *		\$1,738,015	\$434,504	\$1,303,511
TOTAL COSTS		\$3,133,004	\$1,131,998	\$2,001,006
2011				
YTD (7/01/10 thru 12/31/10)				
		50%	50%	
Unisys	Pharmacy (PA)	\$286,192	\$143,096	\$143,096
Provider Synergies		\$324,996	\$162,498	\$162,498
DHH	15% of salaries	\$76,015	\$38,008	\$38,008
ULM *		\$869,405	\$434,702	\$434,702
TOTAL COSTS		\$1,556,608	\$995,655	\$560,953

Table 1.3¹
PA Emergency Override Report (Based on RX-M-025, Error Code 487)

Quarter	Number of PA Overrides
October – December 2010	1,215
July – September 2010	1,268
April – June 2010	1,420
January – March 2010	1,748
October – December 2009	643
July – September 2009	787
April – June 2009	914
January – March 2009	1,051
October – December 2008	880
July – September 2008	561
April – June 2008	1,027
January – March 2008	1,008
October – December 2007	921
July – September 2007	801
April – June 2007	1,002
January – March 2007	1,082
October – December 2006	867
July – September 2006	690
April – June 2006	809
January – March 2006	951
*October – December 2005	4,923
*July – September 2005	887
April – June 2005	660
January – March 2005	696
October – December 2004	842
July – September 2004	947
April – June 2004	1,167
January – March 2004	1,327
October – December 2003	1,353
July – September 2003	1,337
April – June 2003	988
January – March 2003	667
October – December 2002	514
July – September 2002	160

*Prior authorization denial edit temporarily removed due to Hurricane Katrina and Rita.

Analysis of the Utilization Trends for Medical Services and the Preferred Drug List

The Louisiana DHH derives savings from the preferred drug list through supplemental rebates and market shift savings. An analysis of the utilization trends for medical services provided by the state and any correlation to the preferred drug list is provided in the *Louisiana Medicaid Preferred Drug List (PDL) Program Overview and Results February 1, 2011 Provider Synergies report* at <http://www.dhh.louisiana.gov/offices/publications.asp?ID=134&Detail=337>.

CONCLUSION

The Louisiana Department of Health and Hospitals ((DHH) Preferred Drug List (PDL) continues to be successful. The state received \$45,635,734 in supplemental rebates in SFY 2009 and \$42,740,235 in SFY 2010. Although, Federal legislation was implemented changing how rebates are calculated, it is anticipated that the state will continue to realize cost avoidance by continuing to participate in the TOPS program.

BIBLIOGRAPHY

Durand, Salter, et.al. (2005). House Bill No. 369 (Act No. 177) of the 2005 Regular Session.

Jackson and Durand (2004). Senate Bill No. 689 (Act No. 705) of the 2004 Regular Session.

Pharmaceutical and Therapeutics Committee List, www.legis.state.la.us/boards/boardsearch.asp

Preferred Drug List (PDL). www.lamedicaid.com

Provider Synergies(2011). "Louisiana Medicaid Preferred Drug List (PDL) Program Overview and Results February 1, 2011. <http://www.dhh.louisiana.gov/offices/publications.asp?ID=134&Detail=3373> .

APPENDIX 1

ENROLLED

Regular Session, 2004

SENATE BILL NO. 689

BY SENATOR JACKSON AND REPRESENTATIVE DURAND

ACT No. 705

1

AN ACT

2 To amend and reenact R.S. 46:153.3(B)(2)(a)(introductory paragraph) and (b) and to enact
3 R.S. 46:153.3(B)(2)(e), relative to the medical assistance drug program; to provide
4 for the utilization of a prior approval process and criteria related thereto; to provide
5 for rulemaking; to provide for an annual report to the legislature and governor; and
6 to provide for related matters.

7 Be it enacted by the Legislature of Louisiana:

8 Section 1. R.S. 46:153.3(B)(2)(a)(introductory paragraph) and (b) are hereby
9 amended and reenacted and R.S. 46:153.3(B)(2)(e) is enacted to read as follows:

10 §153.3. Medical vendor reimbursements; allowable restrictions; peer-based
11 prescribing and dispensing practice patterns; Medicaid Drug Program
12 Committee

13 * * *

14 B.(1) * * *

15 (2)(a) The department may establish a drug formulary list that utilizes a prior
16 approval process or any other process or combination of processes that prove to be
17 cost-effective in the medical assistance program. At a minimum any prior approval
18 process shall meet all of the following criteria:

19 * * *

20 (b) The department may enter into contractual arrangements to perform the
21 prior approval function and the development of the preferred drug list with a
22 Louisiana school of medicine, a Louisiana school of pharmacy, the fiscal
23 intermediary for the Medicaid program, or such other qualified contractor that it

1 deems appropriate. The department may, at the expiration of any current
2 contractual obligation, enter into contractual arrangements through a public
3 request for proposal process to perform the development of the preferred drug
4 list.

5 * * *

6 R.S. 46:153(B)(2)(c) is all new law.

7 (c) Each year the department shall provide a written and public report to the
8 legislature and the governor thirty days prior to the regular legislative session. The
9 report shall cover:

10 (i) The cost of administering the preferred drug list, including the cost of
11 administering the prior authorization function, the costs of development and
12 maintenance of the preferred drug list and aggregate funds, returned to the federal
13 government related to pharmaceutical rebates.

14 (ii) An analysis of the utilization trends for medical services provided by the
15 state and any correlation to the preferred drug list.

16 * * *

PRESIDENT OF THE SENATE

SPEAKER OF THE HOUSE OF REPRESENTATIVES

GOVERNOR OF THE STATE OF LOUISIANA

APPROVED: _____

APPENDIX 2

ENROLLED

Regular Session, 2005

HOUSE BILL NO. 369

BY REPRESENTATIVES DURAND, SALTER, ALARIO, DORSEY, HAMMETT, AND KATZ AND SENATORS HINES, BAJOIE, HEITMEIER, AND MOUNT

ACT No. 177

Prefiled pursuant to Article III, Section 2(A)(4)(b)(i) of the Constitution of Louisiana.

1 AN ACT

2 To amend and reenact R.S. 46:153.3(C), relative to the medical assistance program; to
3 remove certain drugs from the exemptions to the preferred drug list with prior
4 approval; and to provide for related matters.

5 Be it enacted by the Legislature of Louisiana:

6 Section 1. R.S. 46:153.3(C) is hereby amended and reenacted to read as follows:
7 §153.3. Medical vendor reimbursements; allowable restrictions; peer-based
8 prescribing and dispensing practice patterns; Medicaid Pharmaceutical and
9 Therapeutics Committee

10 * * *

11 C.(1) The department shall not restrict by prior authorization; any anti-
12 retroviral prescription drug, ~~included in certain therapeutic drug classes;~~ as
13 prescribed and determined by a prescribing practitioner licensed by the state; to be
14 medically necessary for the treatment and prevention of HIV/AIDS; and
15 schizophrenia or mental illness with psychotic symptoms hepatitis C

16 (2) Therapeutic classes containing prescription drugs which shall be
17 excluded from any prior authorization provisions shall include the following:

18 (a) Anti-retroviral medications, including Such anti-retroviral prescription
19 drugs include but are not limited to protease inhibitors, non-nucleoside reverse
20 transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, anti-virals, and
21 fusion inhibitors prescribed for the treatment of HIV/AIDS.

1 (b) ~~immunomodulators and Hepatitis C-specific antiviral drugs prescribed~~

2 for the treatment of hepatitis C.

3 (c) ~~Atypical antipsychotic medications prescribed for the treatment of~~

4 schizophrenia or mental illness with psychotic symptoms.

5 (2) The department shall not restrict by prior authorization an atypical

6 antipsychotic medication prescribed for the treatment of schizophrenia or mental

7 illness with psychotic symptoms for a Medicaid recipient that has had a prescription

8 for such atypical antipsychotic paid for by Medicaid during the six months prior to

9 the effective date of the class being placed on the Medicaid preferred drug list.

10 (3) The department shall not restrict by prior authorization an

11 immunomodulator or hepatitis C-specific antiviral drug prescribed for the treatment

12 of hepatitis C for a Medicaid recipient that has had a prescription for such

13 immunomodulator or hepatitis C – specific antiviral drug paid for by Medicaid

14 during the six months prior to the effective date of the class being placed on the

15 Medicaid preferred drug list.

16 (4) The department shall include data from the atypical antipsychotic drug

17 class and the immunomodulator and hepatitis C – specific antiviral drug class with

18 the data collected on all drug classes reviewed on the Medicaid preferred drug list

19 for the annual report to the legislature and governor as required by Subparagraph (c)

20 of Paragraph (2) of Subsection (B) of this Section.

21 * * *

22 Section 2, R.S. 46:153.3(C) is hereby amended and reenacted to read as follows:

23 §153.3. Medical vendor reimbursements; allowable restrictions; peer-based

24 prescribing and dispensing practice patterns; Medicaid Pharmaceutical and

25 Therapeutics Committee

26 * * *

27 C.(1) The department shall not restrict by prior authorization, any

28 prescription drug, included in certain therapeutic drug classes, as prescribed and

29 determined by a prescribing practitioner licensed by the state, to be medically

1 necessary for the treatment and prevention of HIV/AIDS, hepatitis C, and
2 schizophrenia or mental illness with psychotic symptoms.

3 (2) Therapeutic classes containing prescription drugs which shall be
4 excluded from any prior authorization provisions shall include the following:

5 (a) Anti-retroviral medications, including but not limited to protease
6 inhibitors, non-nucleoside reverse transcriptase inhibitors, nucleoside reverse
7 transcriptase inhibitors, anti-virals, and fusion inhibitors prescribed for the treatment
8 of HIV/AIDS.

9 (b) Immunomodulators and Hepatitis C-specific antiviral drugs prescribed
10 for the treatment of hepatitis C.

11 (c) Atypical antipsychotic medications prescribed for the treatment of
12 schizophrenia or mental illness with psychotic symptoms.

13 Section 3. Section 1 of this Act shall cease to be effective on June 30, 2007. Section
14 2 of this Act shall become effective June 30, 2007.

15 Section 4. This Act shall become effective upon signature by the governor or, if not
16 signed by the governor, upon expiration of the time for bills to become law without signature
17 by the governor, as provided by Article III, Section 18 of the Constitution of Louisiana. If
18 vetoed by the governor and subsequently approved by the legislature, this Act shall become
19 effective on the day following such approval.

SPEAKER OF THE HOUSE OF REPRESENTATIVES

PRESIDENT OF THE SENATE

GOVERNOR OF THE STATE OF LOUISIANA

APPROVED: _____

APPENDIX 3

SCR 54 TRACKING

SEY 2003 - Quarter 1 (July - September 2002)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligibles	665,912	779,396	11.1%
Recipients	712,846	562,007	22.5%
Total Scripts Paid	3,283,385	2,987,694	9.9%
Total Scripts Paid with PA	11,730	0	
Rx PA Requests Denied	94	0	

Medications

Accubeb	Budesonide	Kadian	Percocet 7.5-325MG	Vantin
Aceon	Cordene SR	Levaquin	Pleondil	Vascor
Alphex	Cedax	Lorabid	Pletal	Verelan PM
Actiq	Covera-HS	Maxair Autohaler	Prandin	Vicks
Actonel	Cotazur	Maxall	PriLOSEC	Volmax
Advair Diskus	Darvon-N	Maxalt MLT	Prozac Weekly	Zantac Efferdose
Aerobid	Datrol	Myclex	Pulmicort	Zocor
Aerobid M	Datrol LA	Nasacort	Pulmicort Turbuhaler	Zolatt
Alohra	Didronol	Nasacort AQ	QVAR	Zydone
Allegra D	Duoneb	Nasalide	Rhinocort	Zytec
Atace	Dynacirc	Nasarel	Rhinocort Aqua	Zytec D
Alupent	Dynacirc CR	Nexium	Roxicodone	
Amerge	Evista	Nimotop	Safotem	Total Drugs: 97
Atacand	Famvir	Nizatidine	Serevent	
Atacand HCT	Flonase	Noroxin	Solventon Diskus	
Avalide	Floxin	Notivasc	Sporanox	
Avapro	Glucophage-XR	Oxycontin	Tevoran	
Avid	Glucovance	PCE	Tizac	
Beclavent	Glyset	Percocet	Valcyle	
Bixin	Hyzalar	Percocet 10-325MG	Vanconase	
Bixin XL	Imitrex	Percocet 25-325MG	Vancoril	

Rx PA Appeals

Inpatient Days	173,080	156,305	10.7%
ER visits	268,104	241,284	10.4%
Physician Visits	752,047	679,960	10.6%
Physicians w/25+ Patients	4,283	4,053	5.7%
Physicians w/50+ Patients	3,155	2,924	7.9%
Specialist Visits	6,266	6,102	2.5%

SCR 54 TRACKING

SEY 2003 - Quarter 2 (October - December 2002)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>
Eligibles	861,595	799,787	7.7%
Recipients	757,970	639,452	18.5%
Total Scripts Paid	3,776,548	3,286,214	14.9%
Total Scripts Paid with PA	67,908	11,730	
Rx PA Requests Denied	88	94	

Medications

Accutane	Doral	Nasacort	Sporanox
Acon	Duonep	Nasacort AQ	Synalgos DC
Aciphex	Dynadric	Nasolide	Teveten
Actiq	Dynaric CR	Nasorel	Tizac
Actonel	Evista	Naxium	Valcyte
Advair Diskus	Famvir	Nimotop	Vancenase AQ
Aerobid	Flonase	Nizatidine	Vanceril
Aerobid M	Flexin	Noroxin	Vantin
Allogra	Glucophage XR	Norvasc	Vascor
Allogra-D	Glucovance	Opium	
Atace	Glyset	Oestat	Verelan PM
Alpont	Humalog	Oxycontin	Viox
Amerge	Humalog Mix 75/25	PCE	Volmax
Anzemet	Humulin 50/50	Perloc	Xopenex
Aquachloral	Humulin 70/30	Percocet 10.325MG	Zantac Efferdose
Atolin	Humulin L	Percocet 25.325MG	Zantac Granules
Atacand	Humulin N	Percocet 75.325MG	Zocor
Atacand HCT	Humulin R	Pletal	Zolatt
Atrevent	Humulin U	Prandin	Zydone
Avallie	Hyzdar	Pritosec	Zytlo
Avapro	Imitra	Protonix	Zyrtec
Axa	Inderal LA	Provanta Reptab	Zyrtec-D
Betapace AF	Kadian	Provigil	
Bixin	Kytril	Prozac Weekly	Total Drugs: 135
Bixin XL	Lamisil	Pulmicort Turbuhaler	
Capitol w/Codeine	Lantus	QVAR	
Cardene SR	Levaquin	Relenza	
Cedax	Loratad	Rescata	
Climara	Lexel	Restor 7.5MG	
Coreg	Lopraz	Rhinocort	
Covera HS	Lorabid	Rhinocort Aqua	
Cozaar	Lumigan	Roxicodone	
Dantrolum	Mavati Autohaler	Sarafem	
Darvon-N	Mavat	Scopace	
Desomyn	Mavat NLT	Severent	
Detroit	Mazdone	Seroxent Diskus	
Detroit LA	Montax	Sonata	
Didronel	Mycoplex	Spectazole	

Rx PA Appendix

Inpatient Days	191,270	170,122	12.4%
ER visits	335,095	266,116	25.9%
Physician Visits	908,657	781,072	16.3%
Physicians w/25+ Patients	4,375	4,121	6.2%
Physicians w/50+ Patients	3,273	2,966	10.4%
Specialist Visits	6,405	6,261	2.3%

SCR 54 TRACKING

SFY 2003 - Quarter 3 (January - March 2003)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>	
Eligibles Recipients	680,366 760,295	620,445 664,555	7.3% 14.4%	
Total Scripts Paid	3,483,921	3,442,793	1.2%	
Total Scripts Paid with PA	96,162	67,908		
Rx PA Requests Denied	48	88		
Medications				
Accutane	Coreg	Tantus	Provacie	Zantac Effervescent
Aceon	Covera HS	Levoquin	Priosec	Zantac Granules
Aciphex	Cozaar	Levotol	Protonix	Zocor
Actiq	Dantrum	Lorotol	Propotic	Zoloft
Achitella	Darvon-N	Lipitor	Protopin	Zomig
Actonel	Dotrel	Loprox	Provigil	Zydone
Acular	Dotrel LA	Toradol	Prozac Weekly	Zytec
Aerobid	Dictionel	Loxone	Pumecon Respules	Zytree-D
Aerobid-M	Doral	Lunigan	Pumecon Turbulader	
Akineton	Duoneb	Mirax Autohaler	QVAR	
Allergra	Dynacirc	Moxat	Rebil	
Allergra-D	Dynacirc CR	Moxat MLT	Releova	
Altace	Evista	Moxadone	Rescula	
Aluent	Famvir	Montax	Restoril 7.5MG	
Amerge	Femhrt	Myclex	Rhinocort	
Anzemet	Flonase	Nasacort	Rhinocort Aqua	
Anzenept	Flexin	Nasacort AQ	Rowasa	
Astelin	Frava	Nasalide	Roxicodone	
Atacand	Genotropin	Nisarel	Safzon	
Atacand-HCI	Glucophage XR	Nexum	Sarofam	
Atrovont	Glucovance	Nimstop	Songta	
Avaidia	Glyset	Nizatidine	Spectazol	
Avapro	Humalog	Noroxin	Sporanox	
Axicid	Humalog Mix 75/25	Novasc	Synalgos-DC	
Bectoclient	Humatropin	Opium	Tasmar	
Betapace AF	Humulin 50/50	Oxtstat	Triveten	
Blixin	Humulin 70/30	Oxycontin	Tiazac	
Blixin XL	Humulin L	PCE	Forecan	
Canasa	Humulin N	Pontac	Valcete	
Capitol w/Codine	Humulin R	Pentasa	Vancenase AQ	
Cardenal SR	Humulin U	Percocet 10.325MG	Vancett	
Cedax	Hycamtin	Percocet 25.325MG	Vantin	
Cilmara	Imitrex	Percocet 7.5-325MG	Verelan PM	
Cognex	Inderal LA	Petal	Vixx	
Coloraz	Kadian	Prandin	Volmax	
Combipatch	Kytril	Pravachol	Welchol	
Copaxone	Lamisil	Prempro	Xopenex	
Total Drugs: 156				
Rx PA Appeals				
Inpatient Days	189,477	179,520	5.5%	
ER visits	172,380	159,609	8.0%	
Physician Visits	902,217	879,761	2.6%	
Physicians w/25+ Patients	4,224	4,139	2.1%	
Physicians w/50+ Patients	3,135	3,014	4.0%	
Specialist Visits	6,381	6,215	2.7%	

SCR 54 TRACKING

SFY 2003 - Quarter 4 (April - June 2003)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>
Eligibles	887,795	640,597	5.6%
Recipients	603,681	682,726	-17.7%
Total Scripts Paid	3,361,336	3,342,916	0.5%
Total Scripts Paid with PA	119,295	96,162	
Rx PA Requests Denied	29	48	
Medications			
Accubeb	Dantrolen	Texapro	Protonix
Acon	Darvon-N	Tixel	Protopic
Aciphex	Detroit	tipfor	Provantil Ropelabs
Actiq	Detroit LA	Loprax	Provigil
Activella	Didronel	Loratad	Prozac Weekly
Acular	Doral	Lovenox	Pulmicort Turbulizer
Acular Pf	Duoneb	Lumigan	QVAR
Advair Diskus	Dynacirc	Maxair Autohaler	Rebit
Aerobid	Dynacirc CR	Makizone	Rofluna
Aerobid M	Evipta	Mentax	Rescula
Akineton	Famvir	Metaglip	Restori 7.5MG
Alegra	Femhart	Micards	Rhinocort
Alegra-D	Flonase	Mycetex	Rhinocort Aqua
Altace	Flovent	Nasacort	Rowasa
Alupent	Flexin	Nasacort AQ	Roxicodone
Amerge	Forteo	Nasalde	Sazeron
Ancoben	Frova	Nasarel	Saroterm
Anzemet	Genotropin	Nexium	Serevent
Astellin	Glucophage XR	Nimotop	Singular
Atacand	Glucovance	Nordtropin	Sonata
Atacand HCl	Glyset	Noroxin	Spectazolo
Atrovent	Humalog	Novasc	Sporanox
Avalide	Humalog Mix 75/25	Novolog	Synalgos DC
Avapro	Humatropo	Oplum	Tasmar
Axa	Humulin 50/50	Oxistat	Teveten
Bonilar	Humulin 70/30	Oxycontin	Tizac
Betaagon AF	Humulin L	Oxyt	Torecan
Brixin	Humulin N	PCE	Valcyto
Canasa	Humulin R	Peniac	Vancenase AQ
Cardene SR	Humulin U	Pentasa	Vancenil
Cedax	Hyzoor	Percocet 10-325MG	Vantin
Cefex	Imitrex	Percocet 2.5-325MG	Vascor
Cimara	Inderal LA	Percocet 7.5-325MG	Verelan PM
Cognex	Kadian	Petal	ViEND
Colazol	Kytril	Prandin	Viox
Combipatch	Lamisil	Pravachol	Volmax
Copaxone	Lantus	Prempro	Welchol
Covera HS	Levaquin	Previpac	Xopenex
Cozzaar	Levatol	Prilosec	Zetia
Total Drugs: 163			
Rx PA Appeals			
Inpatient Days	188,772	181,503	4.0%
ER visits	166,905	164,943	1.2%
Physician Visits	910,413	875,982	3.9%
Physicians w/25+ Patients	4,337	4,289	1.1%
Physicians w/50+ Patients	3,258	3,184	2.3%
Specialist Visits	6,401	6,203	3.2%

SCR 54 TRACKING

SEY 2004 - Quarter 1 (July - September 2003)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>	
Eligibles	905,644	869,591	4.1%	
Recipients	841,221	712,846	18.0%	
Total Scripts Paid	3,544,437	3,263,385	8.0%	
Total Scripts Paid with PA	141,980	119,295		
Rx PA Requests Denied	28	29		
Medications				
Acbumet	Combipatch	Kemadrin	Prilosec	Welchol
Accupril	Copaxene	Kytril	Protonix	Xopenex
Accutane	Coreg	Lamisil	Propriofen	Zantac Effervesce
Acon	Covera HS	Lantus	Provigil	Zofia
Aciphex	Cezar	Levaquin	Prozac Weekly	Zoloft
Actiq	Dantrolm	Levataol	Pulmicort	Zomig
Activella	Darvon-N	Lexapro	Pulmicort Turbuhaler	Zomig ZMT
Acular	Desoxyn	Lipitor	QVAR	Zydone
Aerobid	Deltol	toprox	Robit	Zyttec
Aerobid M	Detroit LA	Lorabid	Remeron	Zytree D
Akineton	Ditronel	Lovenox	Remeron SOL TAB	
Allora	Doral	Lumigan	Rescata	Total Drugs: 166
Alegra-D	Duroneb	Mazair Autohaler	Restoril	
Altace	Dynacard	Mazdone	Restoril 7.5MG	
Alupent	Dynacirc CR	Mentax	Rhinocort	
Amerge	Effexor XR	Motaglip	Rhinocort Aqua	
Anceboen	Evista	Mycorex	Roxosa	
Anzemet	Famvir	Nasacort	Roxicodone	
Aquachloral	Fenht	Nasacort AQ	Satafilm	
Arthrotec 50	Flonase	Nasarel	Scopace	
Arthrotec 75	Flexin	Nexium	Sorzone	
Atelmin	Fortea	Nizatidine	Somnd	
Atacand	Frova	Noroxin	Sonata	
Atacand HCT	Genotropin	Norvasc	Spectazole	
Atrovent	Glucophage XR	Opium	Sporanox	
Avalide	Glucovance	Oxitot	Strattera	
Avapro	Glyset	Oxycontin	Synalgos DC	
Avid	Humalog	PCE	Tavoton	
Becenotide AQ	Humalog Mix 75/25	Peniac	Tavoton HCT	
Bonilar	Humatrop	Pentasa	Tizac	
Betapace AF	Humulin 50/50	Percocet 10.325MG	Torecon	
Canasa	Humulin 70/30	Percocet 2.5-325MG	Valecyte	
Capitol w/Codene	Humulin L	Percocet 7.5-325MG	Vancendase AQ	
Cardeno SR	Humulin N	Pletal	Vantin	
Cedax	Humulin R	Prandin	Vascor	
Celorex	Humulin U	Prevachol	Verelan PM	
Celoxa	Hyzart	Prempro	VFEND	
Climara	Inderal LA	Prevacid	Vioxx	
Colazol	Kadian	Prevpac	Volmax	
Rx PA Appeals				
Inpatient Days	211,760	173,080	22.4%	
ER Visits	149,013	138,071	7.9%	
Physician Visits	912,298	828,164	10.2%	
Physicians w/25+ Patients	4,634	4,283	8.2%	
Physicians w/50+ Patients	3,498	3,166	10.9%	
Specialist Visits	6,487	6,256	3.7%	

SCR 54 TRACKING

SFY 2004 - Quarter 2 (October - December 2003)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>	
Eligibles	918,679	881,017	+4.3%	
Recipients	884,503	757,970	+16.7%	
Total Scripts Paid	3,679,649	3,776,548	-2.6%	
Total Scripts Paid with PA	147,027	141,980		
Rx PA Requests Denied	45	28		
Medications	3	0		
Accutane	Copaxone	Kytril	Prilosec	Zantac Efferdose
Accupril	Coreg	Lamict	Provigil	Zetia
Accuretic	Covera HS	Lantus	Prozac Weekly	Zomig
Acon	Cezar	Levotol	Pulmicort	Zomig ZMT
Aciphex	Danthrum	Loratad	Pulmicort Turbuhaler	Zytrome
Actiq	Darvon-N	Lipitor	Robit	Zytec
Activella	Desoxyn	Lopros	Relevoza	Zytec Syrup
Acular	Dextrol	Lorabid	Relpax	Zytec-D
Acular LS	Dextrol EA	Lovenox	Rimeder SOL TAB	
Acular PF	Dicronol	Lumigan	Roscula	
Adderall	Doral	Mazol Autohaler	Restolin 7.5MG	
Akineton	Duromax	Mazoline	Rhinocort	
Alpraz	Dynacirc	Mentax	Rhinocort Aqua	
Allegra D	Dynacirc CR	Methoglip	Rowasa	
Altace	Econazole Nitrate	Mycoplex	Roxicodone	
Alpronet	Effexor XR	Nasacort	Sarafem	
Amerge	Evista	Nasacort AQ	Serorevent	
Anzemet	Famvir	Nasarel	Serzone	
Atirotec 50	Femhrt	Neftazodone HCL	Sonata	
Atirotec 75	Flaxin	Nexium	Spectrapax	
Atolin	Foradil	Nimotop	Sporanox	
Atacand	Forsteo	Nizatidine	Strattera	
Atacand HCT	Frova	Noroxin	Syndias DC	
Atrovent	Genotropin	Norvasc	Tasmar	
Axit	Glucophage XR	Oftloxacin	Teveten	
Beclovent	Humalog	Opium	Teveten HCT	
Beconase AQ	Humalog Mix 75/25	Oxistat	Ticlid	
Betapace AF	Humatrope	Oxycontin	Ticlopidine HCL	
Canasa	Humulin 50/50	Oxytrol	Valcyle	
Capitol w/Codeine	Humulin 70/30	PCE	Vancendase AQ	
Cardene SR	Humulin L	Penlac	Vanceril	
Cedax	Humulin N	Pentasa	Vantin	
Cefzil	Humulin R	Percocet 10.325MG	Ventolin HFA	
Colobtex	Humulin U	Percocet 25.325MG	Verelan PM	
Cekra	Hyzoor	Percocet 7.5-325MG	VFEND	
Climara	Inderal LA	Pfefal	Volmax	
Colizol	Ipratropium Bromide	Prevachol	Vospire ER	
Combipatch	Kadian	Prevpac	Welchol	

Rx PA Appeals				
Inpatient Days	188,473	191,270	-1.5%	
ER Visits	146,826	161,352	-9.0%	
Physician Visits	961,707	987,060	-2.6%	
Physicians w/25+ Patients	4,410	4,376	1.0%	
Physicians w/50+ Patients	3,331	3,273	1.8%	
Specialist Visits	6,442	6,406	0.7%	

SCR 54 TRACKING

SPY 2004 - Quarter 3 (January - March 2004)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>
Eligible Recipients	941,649	895,090	5.2%
Total Scripts Paid	919,112	760,295	20.9%
Total Scripts Paid with PA	3,758,741	3,483,921	7.9%
Rx PA Requests Denied	152,032	96,159	58.1%
Rx PA Appeals	23	0	
Medications			
Accipril	Cozart	Lantus	Pulmicort Respules
Accutretic	Dantrolum	Levoflox	Pulmicort Turbuhaler
Aceon	Darvon-N	Lipitor	Robit
Aciphex	Desoxyn	Lopress	Relpax
Actiq	Dextrol	Lorabid	Rimorin SOLTAB
Activella	Dextrol LA	Tovenox	Ruscata
Aculor	Diltiazel	Tumigan	Restoril 7.5MG
Aculor LS	Doral	Maxair Autohaler	Rhinocort
Aculor PF	Duoneb	Maxidone	Rhinocort Aqua
Almetelor	Dyadic	Montair	Rowasa
Allergia	Dyadic CR	Metaglip	Roxicodone
Allergia-D	Econazole Nitrate	Mobic	Sarafem
Atace	Effexor XR	Mycelia	Serevent
Alupent	Emadine	Mycostatin Pastilles	Serzone
Amberg	Evista	Nascort	Sonata
Anzemet	Famvir	Nasocort AQ	Spectazole
Aquachloral	Femhrt	Nasorel	Sporanox
Athrotect 50	Flaxin	Nexium	Strattera
Athrotect 75	Feradil	Nimotop	Synalgos DC
Atellin	Forteo	Nizatidine	Tasmir
Atacand	Frova	Noroxin	Iteveten
Atacand HCT	Genotropin	Novasic	Televetin HCT
Atrovient	Glucophage XR	Oflazacin	Tilda
Avid	Humalog	Opium	Ticlopidine HCL
Beclovent	Humalog Mix 75/25	Oxitot	Valcyfe
Becogenase AQ	Humatrope	Oxycontin	Vancendase AQ
Betapace AF	Humulin 50/50	Oxytrol	Vantin
Canasa	Humulin 70/30	PCE	Veritol HFA
Cardene SR	Humulin I	Pentac	Verelan PM
Cedax	Humulin N	Pentasa	VIEND
Cefzil	Humulin R	Percocet 10.325MG	Volmax
Celebrex	Humulin U	Percocet 2.5.325MG	Vorpite ER
Colexa	Hyzaar	Percocet 7.5.325MG	Welchol
Climara	Inderal LA	Plefar	Zantac Effervesce
Colazol	Ipratropium bromide	Pravachol	Zeta
Combipatch	Kadian	Previpac	Zomig
Copaxone	Kytril	Provigil	Zomig Nasal
Covera-HS	Lamisil	Prozac Weekly	Zomig Spray
Rx PA Appeals	0	0	
Inpatient Days	208,503	189,477	10.0%
ER visits	142,176	172,380	-13.5%
Physician Visits	1,012,691	902,210	12.2%
Physicians w/25+ Patients	4,500	4,224	6.5%
Physicians w/50+ Patients	3,413	3,135	8.9%
Specialist Visits	6,404	6,381	0.4%

SCR 54 TRACKING

SFY 2004 - Quarter 4 (April - June 2004)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>	
Eligibles	943,897	907,804	4.0%	
Recipients	930,935	893,681	15.8%	
Total Scripts Paid	3,589,106	3,360,336	6.6%	
Total Scripts Paid with PA	134,518	119,294	12.8%	
Rx PA Requests Denied	26	0		
Medications				
Accupril	Cozart	Lantus	Pulmicort Respules	Zomig ZMT
Accutane	Dantrolim	Levotol	Pulmicort Turbuhaler	Zydene
Aceon	Darvon-N	Upitor	Rebif	Zytec
Aciphex	Dexosyn	Loprox	Bilipax	Zyrtec Syrup
Actiq	Dotrol	Lorabid	Rimeron SOL TAB	Zyrtec-D
Activella	Dotrel LA	Lovenox	Roscula	
Acular	Didronel	Lumigan	Rofecort 7.5MG	
Acular LS	Doral	Maxair Autohaler	Rhinocort	
Acular FF	Duoneb	Maxidone	Rhinocort Aqua	
Akineton	Dynacirc	Mentax	Rowasa	
Allegra	Dynacirc CR	Motaglip	Roxicodone	
Allegra-D	Econazole Nitrate	Mobic	Sarafem	
Altace	Effexor XR	Mycelox	Serevent	
Alupent	Emadine	Mycostatin Pastilles	Sezanne	
Amerge	Evista	Nascort	Sonata	
Anzemet	Famvir	Nascort AQ	Spectazolo	
Aquachloral	Femstat	Nasarel	Sporanox	
Atiroftec 50	Flaxin	Nexium	Strattera	
Atiroftec 75	Foradil	Nimotop	Synalgos DC	
Atstein	Forteo	Nizatidine	Tasmar	
Atacand	Frova	Noxatin	Teveten	
Atacand HCT	Gonadotropin	Novarsic	Teveten HCl	
Atrovent	Glucophage XR	Oftoxacin	Ticlid	
Axid	Humalog	Opium	Ticlopidine HCl	
Bectrovent	Humalog Mix 75/25	Oxitot	Valecyte	
Beconase AQ	Humatrope	Oxycontin	Vancenase AQ	
Befapace AF	Humulin 50/50	Oxytrol	Varatin	
Comasa	Humulin 70/30	PCE	Ventolin HFA	
Cordene SR	Humulin L	Perilac	Verelan PM	
Cedax	Humulin N	Pentasa	VFEND	
Cetzi	Humulin R	Percocet 10-325MG	Volmax	
Celebrex	Humulin U	Percocet 25-325MG	Vospire ER	
Celexa	Hyzar	Percocet 7.5-325MG	Welchol	
Clilmora	Inderal LA	Pletal	Zantac Efferdose	
Colazol	Ipratropium Bromide	Provachol	Zeta	
Combipatch	Kadian	Prevac	Zomig	
Copaxone	Kytril	Provigil	Zomig Nasal	
Covera-HS	Lamisil	Prozac Weekly	Zomig Spray	
Rx PA Appeals	0	0		
Inpatient Days	207,943	188,772	10.2%	
ER visits	147,882	166,904	-11.4%	
Physician Visits	1,012,691	902,210	12.2%	
Physicians w/25+ Patients	4,525	4,337	4.3%	
Physicians w/50+ Patients	3,475	3,258	6.7%	
Specialist Visits	6,453	6,401	0.8%	

SCR 54 TRACKING

SFY 2005 - Quarter 1 (July - September 2004)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>
Eligible Recipients	962,348	929,195	3.6%
Total Scripts Paid	938,099	841,221	11.6%
Total Scripts Paid with PA	3,559,239	3,544,437	0.4%
Rx PA Requests Denied	116,897	141,943	-16.2%
	23	0	

Medications

Accupril	Detroit	Myceler	Vascor
Accutane	Detroit LA	Nasacort AQ	Ventolin HFA
Acon	Ditronel	Nasarel	Verelan PM
Actiphex	Doral	Neulum	VFEND
Actiq	Duoneb	Nimotop	Vospire ER
Activella	Dynacirc	Nizatidine	Welchol
Akineton	Dynacirc CR	Noroxin	Zastor
Allegra	Eposom	Norvasc	Zantac Etterdose
Allegra-D	Evista	Oflaxacin	Zetsa
Alocril	Femifit	Opium	Zomig
Alomide	Floxin	Oxycontin	Zomig Spray
Altace	Foradil	Oxytrol	Zomig ZM
Alupent	Forteo	PCE	Zymox
Amerge	Frova	Penlac	Zyttec
Anzenmet	Glucophage XR	Pravigard PAC	Zyttec Chew Tabs
Athrotec 50	Heldac	Previpac	Zyttec Syrup
Athrotec 75	Humalog	Provigil	Zyttec-D
Atacand	Humalog Mix 75/25	Prozac Weekly	
Atacand HCT	Humatope	Pulmicort Respules	Total Drugs: 131
Azid	Humulin 50/50	Pulmicort Turbhaler	
Becanase AQ	Humulin 10/30	Rebil	
Cedax	Humulin L	Relpax	
Cefzil	Humulin N	Remeron SOLTAB	
Celebrex	Humulin R	Remicade	
Celexa	Humulin U	Rescal	
Cipro HC	Hyzaar	Rhinopoint Aqua	
Climara	Inderal LA	Rowasa	
Clotrimazole	Kineret	Sazen	
Cognex	Kytril	Sarafem	
Combipatch	Lamisil	Serowent	
Copaxone	Levatol	Serosim	
Cortisporin TC	Lofibra	Sonata	
Covera HS	Loprox	Sporanox	
Coxaar	Lorabid	Strattera	
Crestor	Lovenox	Taveten	
Danthium	Maxair Autohaler	Teveten HCl	
Darvon N	Metoglip	Ticlid	
Dosoxyn	Mirtazapine Sol Tab	Vantin	

Rx PA Appeals	0	0	
Inpatient Days	206,951	211,780	-2.3%
ER visits	142,606	149,013	-5.6%
Physician Visits	922,831	911,605	1.2%
Physicians w/25+ Patients	4,608	4,639	-0.7%
Physicians w/50+ Patients	3,486	3,498	-0.3%
Specialist Visits	6,538	6,487	0.8%

SCR 54 TRACKING

SEY 2005 - Quarter 2 (October - December 2004)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>
Eligibles	922,519	937,255	-3.8%
Recipients	958,021	884,523	+8.3%
Total Scripts Paid	3,692,013	3,679,649	+0.6%
Total Scripts Paid with PA	98,639	146,799	-32.8%
Rx PA Requests Denied	8	0	

Medications

Accupril	Epoprost	Pravilgard PAC	Total Drugs: 114
Aciphex	Evista	Precose	
Actiq	Femstat	Protonix	
Activella	Foradil	Provigil	
Akineton	Forsteo	Prozac Weekly	
Alegria	Frova	Pulmicort Turbohaler	
Allegra D	Holodac	Rabif	
Alosent	Humalog	Relpax	
Alomide	Humalog Mix 75/25	Rimicade	
Alupent	Humatope	Rhinocort Aqua	
Amerge	Humulin 50/50	Rowasa	
Anzemet	Humulin 70/30	Sarafem	
Athrotec 50	Humulin L	Soravent	
Athrotec 75	Humulin N	Sorostin	
Atacand	Humulin R	Sonata	
Atacand HCT	Humulin U	Sporanox	
Avert	Inderal LA	Strattera	
Avid	Kemadrin	Synalgos DC	
Baclofen AQ	Kineret	Taimar	
Cordene SR	Kytril	Ticlid	
Cedax	Lamisil	Ticlopidine HCl	
Celexa	Lofibra	Ventolin HFA	
Cileplirox	Loprox	Verelan PM	
Cipro HC	Lorabid	ViEENO	
Citalopram HBR	Lovenox	Vospire ER	
Climara	Maxair Autohaler	Welchol	
Clotrimazole	Mesalamine	Zaditor	
Combipatch	Myclex	Zantac Errordose	
Copaxone	Nasacort AQ	Zecta	
Cortizeparin TC	Nasarel	Zomig	
Covera-HS	Nasonex	Zomig Sipow	
Crestor	Nimotop	Zomig ZMT	
Danthium	Nizatidine	Zymar	
Darvon-N	Noroxin	Zyrtec	
Dextrol	Oxycontin	Zyrtec Chew Tabs	
Dextrol LA	Pantene	Zyrtec Syrup	
Didronel	Perilac	Zyrtec-D	
Duoneb	Prandin		

Rx PA Appeals	0	0	
Inpatient Days	208,441	188,473	+10.6%
ER visits	146,431	145,826	-0.3%
Physician Visits	1,033,315	961,701	+7.4%
Physicians w/25+ Patients	4,712	4,419	+6.6%
Physicians w/50+ Patients	3,585	3,331	+7.6%
Specialist Visits	6,554	6,449	+1.6%

SCR 54 TRACKING

SFY 2005 - Quarter 3 (January - March 2005)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>
Eligibles	982,544	950,709	3.3%
Recipients	971,355	919,112	5.7%
Total Scripts Pd/M	4,102,040	3,758,741	9.1%
Total Scripts Pd/M with PA	62,459	152,032	-45.8%
Rx PA Requests Denied	10	0	

Medications

Accupril	Evista	Provigt	
Aciphex	Femhrt	Prozac Weekly	Total Drugs: 119
Actiq	Foradil	Pulmicort Respules	
Actrelle	Forleo	Pulmicort Turbohaler	
Akineton	Frova	Quinapril	
Allegra	Holidaq	Quinapril HCL	
Allegra D	Humalog	Robit	
Allegra D 12 Hour	Humalog Mix 75/25	Relpax	
Allegra D 24 Hour	Humatropo	Romicodato	
Alocil	Humulin 50/50	Rhinocort Aqua	
Alomide	Humulin 70/30	Rowasa	
Alupent	Humulin L	Sazom	
Amerge	Humulin N	Sarafem	
Anzemet	Humulin R	Serevent	
Athrotec 50	Humulin U	Sonata	
Athrotec 75	Inderal LA	Sporanox	
Atacand	Itraconazole	Strattera	
Atacand HCT	Kytril	Synagov-DC	
Avoril	Lamisil	Ticlid	
Avid	Levator	Ticlopidine HCL	
Becconase AQ	Lexotil	Vancerend AQ	
Cardon SR	Lofibra	Vencera	
Cedax	Loprox	Ventolin HFA	
Celoxa	Lorabid	Verelan PM	
Diclopirax	Loventox	VFEND	
Cipro HC	Maxair Autohaler	Vospire ER	
Olimara	Mycolex	Welchol	
Clotrimazole	Nasacort AQ	Zaditor	
Combipatch	Nasarel	Zantac Efferdose	
Cepavone	Nasonex	Zetia	
Certoparin-TC	Nizatidine	Zomig	
Covera HS	Noroxin	Zomig Spray	
Crestor	Oxycodone HCL	Zomig ZMT	
Dantrolene	Oxycontin	Zymar	
Dantrolene Sodium	Oxytrol	Zytec	
Darvon-N	Pantac	Zytec Chew Tabs	
Detrol	Prandin	Zytec Syrup	
Detrol LA	Pravigard PAC	Zytec-D	
Didronel	Precose		
Duoneb	Prevpac		
Epoegen	Protonix		

Rx PA Appeals	0	0	
Inpatient Days	215,156	208,503	3.2%
ER visits	170,900	149,176	14.6%
Physician Visits	1,097,656	1,012,691	8.4%
Physicians w/25+ Patients	4,724	4,500	5.0%
Physicians w/50+ Patients	3,634	3,413	6.5%
Specialist Visits	6,582	6,404	2.8%

SCR 54 TRACKING

SFY 2005 - Quarter 4 (April - June 2005)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>
Eligibles	989,899	962,873	2.8%
Recipients	983,512	930,935	5.6%
Total Scripts Paid	3,846,607	3,589,106	7.2%
Total Scripts Paid with PA	78,991	134,518	-41.6%
Rx PA Requests Denied	6	0	

Medications

Accupril	Epoegen	Prostaglandin E1	
Aciphex	Evista	Precose	Total Drugs: 114
Actiq	Fenthet	Protonix	
Activella	Feradil	Provigil	
Akineton	Forteo	Prazac Weekly	
Allegra	Frova	Pulmicort Turbhaler	
Allegra D	Heldac	Rofit	
Aloclar	Humalog	Repxax	
Alomide	Humalog Mix 75/25	Remicade	
Alupent	Humotropin	Rhinocort Aqua	
Ammerge	Humulin 50/50	Rowasa	
Anzemet	Humulin 70/30	Sarafem	
Arthrotec 50	Humulin L	Serevent	
Arthrotec 75	Humulin N	Serostrin	
Atacand	Humulin R	Sonata	
Atacand HCT	Humulin U	Spiranox	
Averil	Inderal LA	Strattera	
Avid	Kemadrin	Synegics DC	
Becotide AQ	Kinect	Tamox	
Cardenal SR	Kytil	Telid	
Cedax	Lamisil	Ticlopidine HCL	
Celeka	Lofatra	Vantelin HFA	
Ciclopirox	Loprox	Verelan PM	
Cipro HC	Lorabid	ViTEND	
Citalopram HBR	Lovenox	Vospire ER	
Cimara	Maxair Autohaler	Welchol	
Clotrimazole	Mesalamine	Zaditor	
Combipatch	Mycelox	Zantac Effervescent	
Copaxone	Nasacort AQ	Zelia	
Cortisporin TC	Nasarel	Zomig	
Covera-HS	Nasonex	Zomig Spray	
Crestor	Nimotop	Zomig ZMT	
Dantrolene	Nizatidine	Zymar	
Darvon-N	Noroxin	Zytac	
Detrol	Oxycontin	Zytac Chew Tabs	
Detrol LA	Pantene	Zytac Syrup	
Didronel	Penlac	Zytac D	
Duobob	Prandin		

Rx PA Appeals	0	0	
Inpatient Days	224,101	207,946	7.8%
ER visits	169,396	147,882	14.5%
Physician Visits	1,021,581	968,985	5.4%
Physicians w/25+ Patients	4,922	4,525	8.8%
Physicians w/50+ Patients	3,602	3,475	9.6%
Specialist Visits	6,657	6,453	3.2%

SCR 54 TRACKING

SEY 2006 - Quarter 1 (July - September 2005)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligible Recipients	1,002,116	981,265	+2.1%
	982,187	939,989	+4.5%
Total Scripts Paid	3,521,320	3,559,239	-1.1%
Total Scripts Paid with PA	109,782	118,697	-7.7%
Rx PA Requests Denied	10	0	

Medications

Accutane	Clotrimazole	Epinor	Rhinocort Aqua
Aciphex	Coreg	Eofbra	Sazeron
Actiq	Cortisporin-TC	Eoprox	Sanctura
Akineton	Covera HS	Lorabid	Saratorm
Allegra	Cymbalta	Mater Autohaler	Seravent
Allegra D 12 Hour	Dantrolium	Mycolex	Serozem
Allegra D 24 Hour	Dantrolene Sodium	Nasacort AQ	Sporanox
Alonal	Darvon-N	Nasarel	Strattera
Alomide	Dextrol	Nasonex	Teveten
Alupent	Dextro LA	Nexum	Teveten HCT
Amerge	Didercon	Nizatidine	Ticlid
Antara	Dipentum	Noroxin	Ticlopidine HCL
Anzenet	Duromed	Novasc	Vancell
Arthrotec 50	Dynacirc	Nutropin	Ventolin HFA
Arthrotec 75	Epopos	Omepazole	Verticare
Asacol	Evista	Opium	VIEND
Atacand	Flonase	Oxycodone HCL	Vospire ER
Atacand HCT	Foradil	Oxycontin	Welchol
Avadile	Forteo	Palladone	Wolbutrin XL
Avandia	Frava	Parlar DC	Zaditor
Avapro	Ganotropin	Parlor SS	Zantac Effervesce
Avizta	Heldac	Perlac	Zegred
Avodart	Humalog	Prandin	Zetia
Axa	Humalog Mix 75/25	Pravachol	Zymar
Becorazak AQ	Humatropo	Pravigard PAC	Zyttec
Benicar	Humulin 50/50	Precose	Zytotec Chew tabs
Benicar HCT	Humulin 70/30	Prevpac	Zytotec Syrup
Caduet	Humulin I	Priosec	Zytotec-D
Canagl	Humulin N	Protonix	
Cedax	Humulin R	Provigil	Total Drugs: 142
Cefex	Humulin U	Prozac Weekly	
Ciclopirox	Imitrex	Pulmicort Respules	
Cipro HC	Imitrex Spray	Pulmicort Turbuhaler	
Claritin	Imitrex tablet	Quinapril	
Claritin Tab Rapid	Itraconazole	Quinapril HCL	
Clinimax Tablet	Kineret	Relpax	
Climara	Kytril	Remicade	
Climara Pro	Lamisil	Renagel	

Rx PA Appeals	0	0	
Inpatient Days	205,247	206,951	-0.8%
ER visits	145,485	140,606	+4.2%
Physician Visits	891,097	922,831	-3.4%
Physicians w/25+ Patients	4,667	4,608	+1.0%
Physicians w/10+ Patients	3,542	3,486	+1.6%
Specialist Visits	6,673	6,538	+2.1%

SCR 54 TRACKING

SFY 2006 - Quarter 2 (October - December 2005)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>	
Eligibles	1,017,356	988,026	3.0%	
Recipients	955,693	958,021	-0.2%	
Total Scripts Paid	3,691,806	3,892,013	-5.1%	
Total Scripts Paid with PA	153,653	98,639	56.8%	
Rx PA Requests Denied	20	0		
Medications				
Abilify	Ciclopirox	Geodon	Norvasc	Symbax
Accutane	Gilexan	Gelulvin V	omeprazole	Tasmir
Acon	Gilexan Ointment	Heliocid	Optivar	Tequin
Aciphex	Cipro	Humalog	Oxistat	Tevefen HCl
Actiq	Cipro HC	Humalog Mix 75/25	Oxycodeone HCl	Ticlid
Akineton	Cipro Suspension	Humatropo	Oxycontin	Ticlopidine HCl
Alamast	Cipro XR	Humulin 50/50	Panlor DC	Vesicare
Allegra	Claritin	Humulin 70/30	Panlor SS	VFEND
Allegra D 12 Hour	Claritin Tab	Humulin L	Paracopa	Vigamox
Allegra D 24 Hour	Claritin Tab Rapid	Humulin N	Pegasys	Vospire ER
Alocril	Climara	Humulin R	Pemoline	Welchol
Alomide	Climara Pro	Humulin U	Penlac	Welsbutrin XL
Alupent	Clotrimazole	Imitrex Tablet	Ponstel	Xalatan
Amerge	Combunox	Istrol	Prandin	Zaditor
Antara	Copegus	Komadrin	Pravachol	Zantac Effendose
Anzemet	Coreg	Kotek	Precos	Zegrid
Atriplate 50	Cortisporin TC	Ketek Pak	Prevacid Napropac	Zetta
Atriplate 75	Covera-HS	Kytril	Prevpac	Zymar
Asacol	Cytel	Levaquin	Prosec	Zyproxa
Atelivin	Gymbalta	Levator	Protonik	Zyproxa Zydus
Atacand	Dantrolene	Lipitor	Provigil	Zytoc
Atacand HCl	Dantrolene Sodium	Lofibra	Przac Weekly	Zytect Chew tabs
Avadex	Desoxyn	Lopraz	Pulmicart Respike	Zytect Syrup
Avandamet	Dietrol	Lotabid	Pulmicart Turbulizer	Zytect - D
Avandia	Dotrol LA	Lunesta	Quixin	
Avapro	Doral	Maxair Autohaler	Relpax	
Avanza	Duoneb	Mentax	Remicade	
Avodart	Dynadre	Metaglip	Ronogel	
Avid	Epopen	Mobic	Rhinocort Aqua	
Becanase AQ	Ertaczo	Myciflex	Ribosphere	
Benicar	Evista	Nattin	Ribavirin	
Benicar HCl	Factive	Nasacort AQ	Sanctura	
Boniva	Fentanyl	Nasarel	Saratern	
Caduet	Fexofenadine HCl	Nasonex	Scopace	
Canasa	Feradil	Noxum	Sorevent	
Cedax	Forteo	Nimotop	Sorostim	
Celebrex	Frava	Nizatidine	Sporanox	
Cefexa	Genotropin	Noroxin	Strattera	
Rx PA Appeals	0	0		
Inpatient Days	202,170	208,441	-3.0%	
ER Visits	158,505	146,431	8.2%	
Physician Visits	845,863	1,033,315	-18.0%	
Physicians w/25+ Patients	4,261	4,712	-9.6%	
Physicians w/50+ Patients	3,229	3,586	-9.9%	
Specialist Visits	7,533	6,554	14.9%	

Total Drugs: 179

SCR 54 TRACKING

SFY 2006 - Quarter 3 (January - March 2006)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>
Eligibles	1,020,597	996,438	2.4%
Recipients	989,066	971,355	-0.2%
Total Scripts Paid	2,549,430	4,102,040	-37.8%
Total Scripts Paid with PA	114,203	82,449	38.5%
Rx PA Requests Denied	21	0	

Medications

Ability	Clozan Ointment	Humalog	Pantol DC	VFEND
Accubob	Cipro	Humulin 50/50	Panlor SS	Vigamox
Acon	Cipro HC	Humulin 70/30	Parcopia	Vospire ER
Aciphex	Cipro Suspension	Humatropo	Pegasys	Welchol
Actiq	Cipro XR	Humulin 70/30	Pemoline	Wellbutrin
Akineton	Claritin Tab	Humulin L	Pentac	Wellbutrin XL
Alamast	Claritin Tab Rapid	Humulin N	Ponstel	Xolatol
Allegro	Climara	Humulin R	Prandin	Zaditor
Allegro D 12 Hour	Climara Pro	Humulin U	Pravachol	Zantac Extended
Allegro D 24 Hour	Combunox	Imitrex Spray	Prevacid Naprapac	Zegret
Aloril	Copegus	Imitrex Tablet	Prilosec	Zeta
Alomide	Coreg	Intfergen	Protonix	Zyprexa
Alupent	Cortesprin IC	Istatol	Provigil	Zyprexa Zydis
Amerge	Cyfort	Ketek	Przac Weekly	Zytoc
Antara	Cymbalta	Ketek Pak	Pulmicort Respules	Zytoc Chew Tabs
Anzemet	Dantrolene	Kytril	Pulmicort Turbuhaler	Zytoc Syrup
Atetra	Dantrolene Sodium	Levoquin	Quixin	Zytoc-D
Athrotect 50	Darvon N	Levotol	Relpax	Total Drugs: 168
Athrotect 75	Dosoxyn	Lipitor	Remicade	
Asacol	Dotrol	Lofibra	Renagel	
Astelin	Dotrol LA	Loratad	Rhinocort Aqua	
Atacand	Didronel	Lunesta	Ribusphere	
Atocand HCT	Dipentum	Montax	Ribavirin	
Avade	Duoneb	Metaglop	Saxen	
Avandamet	Dynacirc	Mobic	Sanctura	
Avandia	Epoegen	Nattin	Sarafem	
Avapro	Ertaczo	Nasorel	Strattera	
Avizta	Evista	Noxium	Symbyax	
Avoidart	Factive	Nimotop	Symdilos DC	
Avid	Fentanyl	Nizatidine	Tasmar	
Beconase AQ	Fexofenadine HCL	Noroxin	Toquin	
Benicar	Foradil	Norvasc	Teveton	
Bonilar HCl	Forteo	Nutropin	Teveton HCl	
Boniva	Frova	Omeprazole	Ticla	
Caduet	Genotropin	Opifvir	Ticlopidine HCL	
Canosa	Geden	Oxistat	Vancenase AQ	
Celotexx	Glipizide-Metformin	Oxycondone HCL	Vancoril	
Ciloxan	Gefulvin V	Oxycontin	Visicare	

Rx PA Appeals	0	0	
Inpatient Days	219,998	215,156	2.3%
ER visits	160,409	170,900	-6.1%
Physician Visits	931,132	1,097,856	-15.2%
Physicians w/25+ Patients	4,460	4,724	-5.6%
Physicians w/50+ Patients	3,368	3,634	-7.6%
Specialist Visits	8,350	6,582	26.9%

SCR 54 TRACKING

SFY 2006 - Quarter 4 (April - June 2006)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>	
Eligible Recipients	1,015,488	1,002,695	1.3%	
	973,305	983,512	-1.0%	
Total Scripts Paid	2,337,056	3,645,607	-39.2%	
Total Scripts Paid with PA	96,199	78,591	22.4%	
Rx PA Requests Denied	13	0		
Medications				
Acifly	Cipro XR	Humalog Mix 75/25	Prilosec	Zyrtec
Accutane	Claritin	Humatropo	Proscar	Zyrtec Chew tabs
Acon	Claritin Red Tabs	Humulin 70/30	Protonix	Zyrtec Syrup
Actiphox	Claritin Syrup	Humulin L	Provigil	Zyrtec D
Actiq	Claritin Tab	Humulin N	Prozac Weekly	
Aikinlon	Claritin Tab Rapidis	Humulin R	Pulmicort Respules	
Allastat	Claritin D 12 Hour	Humulin U	Pulmicort Turbuhaler	
Allerga	Claritin D 24 Hour	Intogen	Quin	
Allerga D 12 Hour	Climara Pro	Innopran XL	Relax	
Allerga D 24 Hour	Colazal	Ketek	Remicade	
Aloril	Combunox	Ketek Pak	Ronexal	
Alomide	Copaxone	Kytril	Rhinocort Aqua	
Alupent	Cortisporin IC	Levofloxacin	Rhasphere	
Ambrin CR	Covera HS	Lipitor	Rheydin	
Amerge	Cyber	Lorabid	Sarafem	
Anacobin	Cymbalta	Magnesibind 400 RX	Sonata	
Antara	Dantrolene	Montax	Shaterra	
Anzemet	Dextro	Metaglip	Symbicat	
Athrotec 50	Dextro LA	Mobic	Tequin	
Athrotec 75	Didronel	Natrin	Teveten	
Astellin	Duoneb	Nasarel	Tevefen HCl	
Atacand	Dynacirc	Nimotop	Ticlid	
Atacand HCl	Epopos	Norvasc	Ticlopidine HCl	
Avalde	Ertaczo	Omacer	Triglide	
Avandia	Evista	Omeprazole	VEND	
Avanza	Factive	Optivar	Vigamox	
Axit	Fentanyl	Oxatol	Vospire ER	
Beclavent	Ferroxadine HCl	Oxydone HCl	Welchol	
Bicronate AQ	Foradil	Oxycontin	Wellbutrin SR	
Boniva	Forteo	Panter DC	Xalatan	
Budeprion SR	Fortical	Panter SS	Zodfor	
Bupropion HCl	Frova	Parcopa	Zantac Efferdose	
Caduet	Genotropin	Penlac	Zegrid	
Cardenia SR	Glibpido-Metformin	Ponstel	Zeta	
Celebrex	Grifulvin V	Prandin	Zomig	
Citizan	Griseofulvin	Pravachol	Zomig ZMT	
Cipro HC	Humalog	Pravastatin Sodium	Zyprexa	
Cipro Suspension	Humalog Mix 50/50	Prevacid Napropac	Zyprexa Zydis	
Rx PA Appeals	0	0		
Inpatient Days	219,320	224,101	-2.1%	
ER visits	167,364	169,396	-1.2%	
Physician Visits	930,777	1,021,581	-8.9%	
Physicians w/25+ Patients	4,541	4,922	-7.7%	
Physicians w/50+ Patients	3,515	3,809	-7.7%	
Specialist Visits	7,736	6,657	16.2%	

SCR 54 TRACKING

SFY 2007 - Quarter 1 (July - September 2006)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligibles	999,363	1,021,111	-2.1%
Recipients	942,339	992,187	-4.1%
Total Scripts Paid	2,075,266	3,521,320	-41.1%
Total Scripts Paid with PA	77,883	109,782	-29.1%
Rx PA Requests Denied	14	0	
Medications			
Abilify	Climara Pro	Kefek	Quien
Accutab	Colazal	Ketek Pak	Relepkax
Acon	Combinox	Ketotifen Fumarate	Romidecadate
Acliphex	Copaxone	Kytril	Rhinocort Aqua
Actiq	Cortisporin-TC	Levaquin	Ribasok
Actionel with Calcium	Covera HS	Lipitor	Ribosphere
Alamast	Cumbatta	Lorabid	Ribavirin
Allegra	Darvon-N	Magnebind 400 Rx	Sarafem
Allegra-D 12 hour	Deltol	Menstar	Sonata
Allegra-D 24 hour	Deltol LA	Metaglip	Strattera
Alacat	Didronel	Mobic	Symbrys
Alomide	Duoneb	Nutrin	Tegurin
Alupent	Dynacirc	Nasorel	Teveten
Ambien CR	Epogen	Noroxin	Toleveten HCl
Amerge	Ertaczo	Novasac	Ticla
Antara	Evista	Nutropin	Ticlopidine HCl
Anzemet	Factive	Omecozol	Triglide
Athrotec 50	Fentanyl	Omeprazole	VIEND
Athrotec 75	Fexofenadine HCl	Optivar	Vigamox
Atdin	Finasteride	Oxitrat	Vospire ER
Atacand	Foradol	Oxycodone HCl	welchol
Atacand HCT	Forteo	Oxycontin	Wellbutrin SR
Avanza	Fortival	Panlor DC	Xalatan
Becondase	Frava	Panlor SS	Zaditor
Boniva	Gonotropin	Parcopa	Zegerid
Budeprion SR	Geodon	Pental	Zetta
Bupropion HCl	Glibizide Metformin	Pontol	Zomig
Caduet	Gritulvin V	Prandin	Zomig ZM
Celebrex	Humalog	Pravachol	Zytlo
Ciloxan	Humalog Mix 50/50	Pravastatin sodium	Zyprexa
Cipro HC	Humalog Mix 75/25	Prevacid Naprapac	Zyprexa Zylas
Cipro Suspension	Humatropo	Prilosec	Zytrec
Cipro XR	Humulin 70/30	Proscar	Zytrec Chow tabs
Claritin RediTabs	Humulin N	Protonix	Zytrec Syrup
Claritin Syrup	Humulin R	Provigil	Zytrec D
Claritin Tab	Infergen	Prozac Weekly	
Claritin - D 12 Hour	Innoven XL	Pulmicort Respules	
Claritin - D 24 Hour	Istrol	Pulmicort Turbulhaler	
			Total Drugs: 149
Rx PA Appeals	0	0	
Inpatient Days	195,568	205,247	-4.7%
ER visits	144,075	146,485	-1.6%
Physician Visits	777,642	891,097	-12.7%
Physicians w/25+ Patients	4,371	4,667	-6.3%
Physicians w/50+ Patients	3,326	3,642	-6.1%
Specialist Visits	7,661	6,673	14.8%

SCR 54 TRACKING

SFY 2007 - Quarter 2 (October - December 2006)

Information Category	Current Quarter	Previous Year Quarter	Percent Change	
Eligible Recipients	993,534	1,029,684	-3.5%	
	932,520	955,693	-2.4%	
Total Scripts Paid	2,458,987	3,691,806	-33.4%	
Total Scripts Paid with PA	91,399	153,653	-40.5%	
Rx PA Requests Denied	9	0		
Medications				
Abilify	Olmendro	Loratad	Prevacid Naprapac	Xolatad
Ability Disulfmit	Celazal	Lipitor	Prilosoc	Zaditor
Accutane	Combunox	Toprox	Proquin XR	Zegrid
Aciphex	Copaxone	Lopirox Shampoo	Proscar	Zetlor
Actiq	Cortipsin-TC	Lorabid	Protonik	Zelia
Actionel	Cymbalta	Magnebind 400 RX	Provigil	Zoloff
Allergra	Dexosyn	Mucolofenamate Sodium	Prazac Weekly	Zomig
Allergra-D 12 Hour	Diflazac	Metaplip	Pulmicort Respules	Zomig ZMT
Allergra-D 24 Hour	Difrol LA	Metaproterenol Sulfate	Pulmicort Turbulader	Zylo
Alomide	Duoneb	Mobic	Quixin	Zyptixa
Alupent	Dynacirc	Nasarel	Ranidol	Zyptixa Zids
Ambien CR	Epopen	Nimotop	Razadyne	Zytac
Amberge	Ertaczo	Novasc	Razadyne ER	Zytac Chow Tabs
Antara	Evista	Novolin 70/30	Relpax	Zytac Syrup
Anzemet	Factive	Novolin N	Remicade	Zytac D
Apidra	Fentanyl	Novolin R	Rhinocort Aqua	
Attritotec 50	Feoxethiadine HCL	Novolog	Ribavirin	Total Drugs: 167
Attritotec 75	Finasteride	Novolog Mix 70/30	Ritalin LA	
Atacand	Futicasone Propionate	Nutropin	Sertraline HCL	
Atacand HCT	Fordol	Omacer	Sonata	
Avizta	Forteo	Omepratazole	Spectracet	
Becconase AQ	Fortical	Omnicef	Spiranox	
Budeprion SR	Frova	Opana	Strattera	
Bupropion HCL	Fulvicin U/F Tablet	Opana ER	Symbax	
Caduet	Genotropin	Opium	Taveten	
Cardene SR	Glipizide Metformin	Optivar	Teveten HCT	
Celorex	Gritulvin V	Orencla	Ticlopidine HCL	
Clexan	Gritulvin V Tablet	Oxistat	Triglide	
Clixan Ointment	Grecofulvin	Oxycodone HCL	Ultram ER	
Cipro HC	Humalog Mix 50/50	Oxycontin	Uniretic	
Cipro Suspension	Humattrope	Pantol DC	Univasc	
Cipro XR	Innophan XL	Pantol SS	Ventolin HFA	
Claritin RediTabs	Istadol	Parcopa	ViEND	
Claritin Releasers	Itraconazole	Pantac	Viganox	
Claritin Syrup	Ketek	Pantel	Vuson	
Claritin Tab	Ketek Pak	Prandin	Welchol	
Claritin-D 12 Hour	Kytril	Pravachol		
Claritin-D 24 Hour	Levaquin	Pravastatin Sodium	Wellbutrin SR	
Rx PA Appeals	0	0		
Inpatient Days	215,219	202,170	6.5%	
ER visits	152,848	158,606	-3.6%	
Physician Visits	691,214	646,863	5.2%	
Physicians w/25+ Patients	4,405	4,261	3.4%	
Physicians w/50+ Patients	3,322	3,229	2.9%	
Specialist Visits	7,299	7,533	-3.1%	

SCR 54 TRACKING

SFY 2007 - Quarter 3 (January - March 2007)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligible Recipients	952,534	1,035,117	-8.0%
	922,857	969,056	-4.8%
Total Scripts Paid	2,583,646	2,549,430	1.3%
Total Scripts Paid with PA	93,715	114,203	-17.9%
Rx PA Requests Denied	7	0	
Medications			
Ability	Clinara Pro	Nasarel	Ritalin LA
Ability Discmelt	Colazal	Nimotop	Sertraline HCL
Accutane	Combunox	Nervac	Sonata
Aciphex	Copaxane	Novolin 70/30	Spectracef
Actiq	Cortisporin-TC	Novolin N	Sporanox
Actonel	Covera HS	Novolin R	Strattera
Adderall XR	Cymbalta	Novolog	Symbax
Alavert	Darvon-N	Novolog Mix 70/30	Teveten
Allergra	Dotrel	Nutropin	Teveten HCl
Allergra Sup	Dotrel LA	Otnacor	Ticlid
Allergra-D 12 Hour	Dordil	Omepazole	Ticlopidine HCL
Allergra-D 24 Hour	Duoneb	Omnicef	Triglide
Alocril	Dynapac	Opana	Ultram ER
Alomide	Epogen	Opana ER	Uniretic
Alupent	Erlacto	Optivar	Univasc
Ambien CR	Evista	Oxistat	Ventolin HFA
Amerigo	Factive	Oxycodeone HCL	VITEND
Amivive	Fontanyl	Oxycontin	Vigamox
Antara	Faxofenadine HCL	Parlon DC	Vospire ER
Anzemet	Finasteride	Parlon SS	Vusion
Apidra	Fluticasone Propionate	Parcopa	Welchol
Arthrotec 50	Forast	Pantac	Wobulin SR
Arthrotec 75	Forleo	Pensol	Xalatan
Atacand	Fortical	Prandin	Zaditor
Atacand HCl	Frova	Pravachol	Zegerid
Avanza	Genotropin	Pravastatin Sodium	Zelbor
Baclofen-AQ	Glipizide-Metformin	Prevacid/Naprapac	Zefia
Budeprion SR	Glitulin V Tablet	Prilosec	Zomig
Buproprion HCL	Humatropo	Proguan XL	Zomig ZM
Caduet	Innoven XL	Proscar	Zybrexa
Cardene SR	Istatol	Protonix	Zyflexa Zydis
Celebrex	Itraconazole	Provigil	Zytec
Claritin Ointment	Ketek	Prazac Weekly	Zytec Chew Tabs
Cipro HC	Ketek Pak	Pulmicort Respules	Zytec Syrup
Cipro Suspension	Kytril	Pulmicort Turbuhaler	Zytec-D
Cipro XR	Levaquin	Quikin	
Ciprofloxacin Suspension	Lipitor	Ranidol	
Clarimax	Lopax Shampoo	Razadyme	
Clarimax Repetabs	Loratad	Razadyme ER	
Clarimax Syrup	Meclofenamate Sodium	Relpax	
Clarimax Tab	Melaglip	Remicade	
Clarimax-D 12 Hour	Mobic	Rhinocort Aqua	
Clarimax-D 24 Hour	Moxipril HCL	Ribavirin	
Total Drugs: 165			
Rx PA Appeals	0	0	
Rx PA Medical Reviews	1		
Inpatient Days	229,892	219,998	4.5%
ER visits	167,021	160,409	4.1%
Physician Visits	907,670	931,132	-2.5%
Physicians w/25+ Patients	4,402	4,460	-1.3%
Physicians w/50+ Patients	3,376	3,358	0.5%
Specialist Visits	6,707	8,350	-19.7%

SCR 54 TRACKING

SFY 2007 - Quarter 4 (April - June 2007)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligibles	951,437	1,028,502	-6.5%
Recipients	939,536	973,305	-3.5%
Total Scripts Paid	2,420,379	2,337,055	3.6%
Total Scripts Paid with PA	95,649	96,199	-0.4%
Rx PA Requests Denied	5	0	

Medications

Ability	Darvon-N	Nordtropin	Sertraline HCL
Ability Discmoff	Detroit	Nordtropin Nordflex	Sonata
Accubeb	Detroit LA	Novolin 70/30	Spectracef
Acliphex	Ditronel	Novolin N	Sporanox
Actiq	Dipentum	Novolin R	Strattera
Actionel	Ditropan XL	Novolog	Symbax
Alamast	Doral	Novolog Mix 70/30	Teveten
Allegra	Duoneb	Noxafil	Teveten HCL
Allegra-D 12 Hour	Eposigen	Ornadez	Ticlid
Allegra-D 24 Hour	Erfazio	Omeprazole	Ticlopidine HCL
Alomil	Estazolam	Omnicef	Triglide
Alominda	Etidronate Disodium	Opana	Ultram ER
Alupent	Evista	Opana ER	Urictrol
Ambien	Exubera Comb. Pack 12	Optivar	Urvasc
Antara	Exubera Comb. Pack 15	Oxistat	Ventolin HFA
Anzemet	Exubera Kit	Oxycodeone HCL	ViEND
Apidra	Factive	Oxycontin	Vigamox
Arthrotec 50	Fenofibrate	Pantol DC	Vorpiox ER
Arthrotec 75	Fentanyl	Parcopa	Vusion
Atacand	Fexofenadine HCL	Patanol	Welchol
Atacand HCT	Flurazepam HCL	Peroxic	Wellbutrin XL
Avanza	Fluticasone Propionate	Pentasa	Xolatran
Avert	Foradil	Ponstol	Zaditor
Azact	Forleo	Prandin	Zegerid
Becconase AQ	Fortical	Pravachol	Zetia
Caduet	Frova	Pravastatin Sodium	Zomig
Celdrin	Grufulin V Tablot	Prevacid Naprapac	Zomig ZMT
Celebrex	Humatrope	Prilosec	Zyprexa
Clioxan Ointment	Infergan	Proquin XR	Zyptixa Zydus
Cipro HC	Innropin XL	Prisom	Zytect
Cipro Suspension	Istadol	Protonix	Zytect Chew Tabs
Cipro XR	Itraconazole	Provigil	Zytect Syrup
Ciprofloxacin ER	Ketek	Prozac Weekly	Zytect D
Ciprofloxacin Suspension	Ketek Pak	Pulmicort	
Claritin Releas tabs	Kytril	Pulmicort Resposes	
Claritin Tab	Levaqulin	Pulmicort Turbulizer	
Claritin-D 12 Hour	Loprox Shampoo	Quixin	
Claritin-D 24 Hour	Meclofenamate Sodium	Ranilor	
Combunox	Metaproteterenol Sulfate	Razadyne	
Copegus	Mobic	Relpax	
Covera-HS	Nasarel	Remicade	
Cymbalta	Nofazodone HCL	Rhinocort Aqua	
Dalmane	Nimotop	Ritalin LA	

Total Drugs: 164

Rx PA Appeals	0	0	
Rx PA Medical Reviews	0	0	
Inpatient Days	220,852	219,320	0.7%
ER visits	155,503	167,364	-7.1%
Physician Visits	891,973	930,777	-4.2%
Physicians w/25+ Patients	4,761	4,641	4.8%
Physicians w/50+ Patients	3,745	3,515	6.5%
Specialist Visits	6,810	7,736	-12.0%

SCR 54 TRACKING

SFY 2008 - Quarter 1 (July - September 2007)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>
Eligibles	987,061	1,017,195	-3.0%
Recipients	920,734	942,399	-2.3%
Total Scripts Paid	2,164,657	2,075,286	5.3%
Total Scripts Paid with PA	77,932	77,683	0.1%
Rx PA Requests Denied	27	0	

Medications

Ability	Dipentum	Norditropin Norditropin	Sporanox
Ability Discmelt	Ditropan XL	Novolin 70/30	Strattera
Accutane	Duoneb	Novolin N	Symbax
Aciphex	Emsam	Novolin R	Tamar
Actiq	Epopos	Novolog	Teveton
Actonal	Entaczo	Novolog Mix 70/30	Truveten HCl
Actonal with Calcium	Estazolam	Noxafil	Ticlid
Allegra	Etidronate Disodium	Nutropin	Triglide
Allegra-D 12 Hour	Evista	Ornacor	Utram ER
Allegra-D 24 Hour	Exubera Comb Pack 12	Omeprazole	Uniretic
Aloclar	Exubera Comb Pack 15	Omnicef	Univasc
Aloamide	Exubera Kit	Opana	Ventolin HFA
Alupent	Exubera Patient Pack	Opana ER	VFEND
Ambien	Factive	Optivar	Vigamox
Antara	Fenofibrate	Oxistat	Vospire ER
Anzemet	Fentanyl	Oxycodone HCl	Vuspin
Apidra	Fexofenadine HCl	Oxycontin	Welchol
Athrotec 50	Flurazepam HCl	Panlor DC	Wellbutrin XL
Athrotec 75	Fluticasone Propionate	Pentac	Xalatan
Atacand	Foradil	Pentasa	Xolegel
Atacand HCT	Forteo	Pentel	Zaditor
Avinza	Fortical	Pranthia	Zegerid
Axert	Frova	Pravachol	Zeta
Bacanase AQ	Gritulytin V Tablet	Pravastatin Sodium	Zomig
Caduet	Humalog	Prevacid Naprapac	Zomig ZM
Celebrex	Humatope	Priosec	Zyprexa
Clozapine	Interferon	Prosom	Zyprexa Zydus
Clexan Ointment	Innopran XL	Protonix	Zytec
Cipro HC	Istadol	Provigil	Zytec Chew Tabs
Cipro Suspension	Itraconazole	Prazosin Weekly	Zytec Syrup
Cipro XR	Ketek	Pulmicort Respules	Zytec-D
Claritin Releas tabs	Kytril	Pulmicort Turbuhaler	
Claritin Tab	Levaquin	Quilen	
Claritin - D 12 Hour	Lofibra	Ranidol	
Claritin - D 24 Hour	Lopax Shampoo	Robitol	
Combunox	lorabid	Relpax	
Copegus	Lovaza	Romicade	
Cymbalta	Meclofenamate Sodium	Rhinocort Aqua	
Dalmane	Mobic	Ritalin LA	
Darvon-N	Nasarel	Serratio HCl	
Detroit	Nefazodone HCl	Sonata	
Detroit LA	Nimotop	Spectracef	
Didronel	Norditropin		

Total Drugs: 160

Rx PA Appeals	0	0
Rx PA Medical Reviews	1	
Inpatient Days	213,013	195,568
ER visits	134,165	144,075
Physician Visits	797,259	777,642
Physicians w/25+ Patients	4,421	4,371
Physicians w/50+ Patients	3,367	3,326
Specialist Visits	6,232	7,661

SCR 54 TRACKING

SFY 2008 - Quarter 2 (October - December 2007)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>
Eligibles	1,000,550	1,011,097	-1.0%
Recipients	952,665	932,520	2.2%
Total Scripts Paid	2,571,849	2,458,987	4.6%
Total Scripts Paid with PA	63,618	91,399	-8.5%
Rx PA Requests Denied	13	0	
Medications			
Abelcet	Coreg CR	Lovaza	Ranidol
Ability Disrupt	Cymbalta	Meclofenamate Sodium	Razadyne
Accubeb	Dalmane	Mefenamic Acid	Razadyne ER
Aciphex	Darvon-N	Mentax	Rebetolet
Actiq	Dextro	Micards	Rebox
Alamist	Dextro LA	Metoprolol HCL	Remicade
Allegra	Dihydroal	Monopril Hydrochlorothiazide	Rhinocort Aqua
Allegra Susp	Ditropan XL	Nasarel	Ritalin LA
Allegra-D 12 Hour	Duoneb	Nefazodone HCL	Sertraline HCL
Allegra-D 24 Hour	Erimam	Norditropin	Sonata
Aloril	Epogen	Norditropin Norditrex	Sporanox
Alomide	Ertaizo	Noxafil	Strattera
Alupent	Estazolam	Nutropin	Suprax
Amblen	Evista	Omacor	Symbax
Antara	Exelderm	Omeprazole	Tekturna
Anzemet	Exubera Comb Pack 12	Omnicef	Teveten
Aplidra	Exubera Kit	Omnitrope	Ticlid
Arthrotec 50	Exubera Patient Pack	Opana	Ticlopidine HCL
Arthrotec 75	Factive	Opana ER	Triglide
Asmonex	Fazaclo	Optivar	Ultram ER
Atacand	Fencitabrate	Oxistat	Uniretic
Atacand HCT	Fentanyl	Oxycodone HCL	Univasc
Augmentin XR	Fentora	Oxycontin	VEND
Avinza	Fexofenadine HCL	Panlor DC	Welchol
Avorl	Flurazepam HCL	Paxil CR	Wellbutrin XL
Avtact	Fluticasone Propionate	Penlac	Xalatan
Becconase AQ	Foradil	Pentasa	Zastor
Biaxin XL	Forfex	Pexeva	Zegerid
Boniva	Fertical	Pondel	Zetta
Cardene SR	Grifulvin Tablet	Prandin	Zmax
Children S Claritin	Humatope	Pravachol	Zofran
Childrens Claritin	Innoprano XL	Pravastatin Sodium	Zofran ODT
Clorox Ointment	Istafol	Prevacid Naproxac	Zomig
Cipro HC	Itraconazole	Pritosec	Zomig ZMT
Cipro Suspension	Ketek	Prisom	Zymar
Cipro XR	Kytril	Protonix	Zyprexa
Clarinet Releve tabs	Lamisil	Provigil	Zyprexa Zydis
Clarinet Tab	Levaquin	Prozac Weekly	Zytac
Clarinet-D 12 Hour	Udoa	Pulmicort	Zytac Chew Tabs
Clarinet-D 24 Hour	Uptor	Pulmicort Flathaler	Zytac Syrup
Combunox	Loprox	Pulmicort Respules	Zytac D
Comtan	Loprox Shampoo	Quixin	
			Total Drugs: 172
Rx PA Appeals	0	0	
Rx PA Medical Reviews	0	0	
Inpatient Days	225,321	215,219	4.7%
ER visits	160,325	152,844	4.9%
Physician Visits	887,568	891,214	-0.4%
Physicians w/25+ Patients	4,548	4,405	3.2%
Physicians w/50+ Patients	3,466	3,322	4.3%
Specialist Visits	6,446	7,299	-11.7%

SCR 54 TRACKING

SFY 2008 - Quarter 3 (January - March 2008)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>
Eligible Recipients	1,019,886	971,374	5.0%
Total Scripts Paid	983,008	922,857	4.4%
Total Scripts Paid with PA	2,660,427	2,583,646	3.0%
Rx PA Requests Denied	71,896	93,715	-23.3%

Medications

Ability	Copegus	Nefazodone HCL	Teveten
Ability Dismett	Coreg CR	Nordrapin	Ticlid
Accupex	Cymbalta	Nordrapin Nordflex	Ticlopidine HCL
Acon	Dalmane	Noradil	Triglide
Aciphex	Dexosyn	Omacor	Ultram ER
Actiq	Dextrol	Omeproazole	Uniretic
Actonel with Calcium	Dextrol LA	Omnicef	Univasic
Alamast	Didronel	Opana	VFEND
Alegra	Ditropan XL	Opana ER	Welchol
Alegra Susp	Doral	Ophzar	Welbutrin XL
Alegra-D 12 Hour	Duoneb	Orenzia	Xalatan
Alegra-D 24 Hour	Emsam	Oxitot	Zaditor
Alocril	Eponox	Oxycodone HCL	Zegrid
Alomide	Ertaczo	Oxycodone HCL-Ibuprofen	Zetia
Alupent	Estazolam	Oxycontin	Zmax
Ambien	Etidronate Disodium	Panlor DC	Zofran
Amelvive	Evista	Pantoprazole Sodium	Zofran ODT
Ancobon	Exelderm	Paxil CR	Zomig
Antara	Factive	Pentac	Zomig ZMT
Anzemet	Fazacio	Pentasa	Zylo
Apidra	Fenofibrate	Pexeva	Zymar
Arthrotec 50	Fontanyl	Ponstel	Zyprexa
Arthrotec 75	Fontora	Prandin	Zyprexa Zydis
Asmanex	Feokretenadine HCL	Pravachol	Zytec
Atacand	Flurazepam HCL	Pravastatin Sodium	Zytec Chew Tabs
Atacand HCT	Fluticasone Propionate	Prevacid Napropac	Zytec Syrup
Augmentin XR	Foradil	Prilosec	Zytec-D
Avinza	Forteo	Protonix	
Azent	Fortical	Provigil	Total Drugs = 171
Azlect	Frovia	Prozac Weekly	
Becconase AQ	Gnifulin Tablet	Pulmicort	
Brixin XL	Humatropo	Pulmicort Flexhaler	
Boniva	Innopran XL	Pulmicort Respules	
Caduet	Iquix	Pulmicort Turbuhaler	
Caldura XL	Itraconazole	Quibin	
Cetirizine HCL	Ketek	Ranidol	
Childrens Claritin	Kytril	Razadyne	
Cicloplex	Levaquin	Razadyne ER	
Clavox Ointment	Lialda	Relpax	
Cipro HC	Loprox	Remicade	
Cipro Suspension	Loprox Shampoo	Rhinocort Aqua	
Cipro XR	Lovaza	Ritalin LA	
Clarimax Releasers	Moclofenamate Sodium	Sonata	
Clarimax Tab	Mefenamic Acid	Spexanax	
Claritin - D 12 Hour	Montax	Strattera	
Claritin - D 24 Hour	Moxipril HCL	Suprax	
Combunox	Moxipril-Hydrochlorothiazide	Symbalar	
Comtan	Nasarel	Tekturna	

Rx PA Appeals	0	0	
Rx PA Medical Reviews	1	0	
Inpatient Days	224,745	229,892	-2.2%
ER visits	176,078	167,021	5.4%
Physician Visits	931,686	907,670	2.6%
Physicians w/25+ Patients	4,538	4,402	3.1%
Physicians w/50+ Patients	3,466	3,376	2.7%
Specialist Visits	6,401	6,707	-4.6%

SCR 54 TRACKING

SFY 2008 - Quarter 4 (April - June 2008)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligible Recipients	1,032,759	978,472	5.5%
Total Scripts Paid	2,662,985	2,420,379	10.0%
Total Scripts Paid with PA	29,973	102,453	-21.9%
Rx PA Requests Denied	13	0	
Medications			
Abilify	Claritin Rediflatabs	Gatiflvin V Tablet	Prevacid Naprapac
Ability Discreet	Claritin Syrup	Humatropin	Zanaflex
Accutane	Claritin Tab	Innopran XL	Zegretol
Accupunt	Claritin D 12 Hour	Iquix	Zetia
Accuretic	Claritin D 24 Hour	Itraconavazole	Zmax
Aciphex	Cortef	Kytril	Zocor
Actiq	Coreg CR	Lorazepam	Provigil
Advcior	Crestor	Lulida	Prazac Weekly
Alamast	Cymbalta	Lopufen	Pulmicort
Allegra	Dalmane	Loprox Gel	Pulmicort Flexhaler
Allegra ODT	Dantrolene	Loprox Shampoo	Pulmicort Respules
Allegra-D 12 Hour	Dantrolene Sodium	Lovaza	Pulmicort Turbuhaler
Allegra-D 24 Hour	Darvon-N	Maxalt	Quinapril HCL
Alocril	Dextrofet	Mavart MII	Quinapril-Hydrochlorothiazide
Alomide	Diflunisal	Mefenamic Acid	Quinagrel
Altopenx	Ditropan XL	Mentalax	Quinidin
Alupent	Doral	Metaproterenol Sulfate	Ranidol
Ambien CR	Duobieb	Moxipri HCL	Razadyme
Amerge	Durogesic	Moxipri Hydrochlorothiazide	Razadyme ER
Amrix	Epopen	Monopril	Relpar
Antara	Ertaczo	Monopril HCL	Remicade
Anzemet	Etrazon	Nasarel	Rhinocord Aquia
Apkira	Etrazonam	Nefazodone HCL	Ritalin LA
Antria	Evista	Neo-Frazin	Somprex D
Arthrotec 50	Exekdorm	Noormycin Sulfate	Simvastatin
Arthrotec 75	Exelon	Nothex	Skelaxin
Asmanex	Extra	Omacer	Soma
Atacand	Factive	Omeprazole	Sporanox
Atacand HCL	Fazolo	Ornicipref	Strattera
Augmentin XR	Fenofibrate	Opana	Suprax
Aviza	Fenoglide	Opana ER	Symbizax
Avret	Fentanyl	Optivar	Takz
Azospite	Fentanyl Citrate	Oronicia	Tekturna
Bactroban	Fentora	Orphenadrine Citrate	Toveten
Beconase AQ	Femid	Oestraf	Ticlid
Biaxin XL	Fexofenadine HCL	Oxybutynin Chloride ER	Tickloidine HCL
Boniva	Flagyl ER	Oxycodone HCL	Triglide
Brovana	Furazepam HCL	Oxycontin	Ultram ER
Caduet	Fluticasone Propionate	Parlor DC	Uniretic
Cetirizine HCL	Foradil	Pantoprazole Sodium	Univasc
Childrens Claritin	Forteo	Parl CR	Vermayst
Ciloxan	Fortical	Penlac	VFEND
Ciloxan Oint	Fosinopril Sodium	Pentasa	Welchol
Ciloxan Ointment	Fosinopril Hydrochlorothiazide	Perforomist	Wellbutrin XL
Cipro HC	Forsenel	Pexeva	Xalatan
Cipro Suspension	Frova	Ponstel	Xifaxan
Cipro XR	Genotropin	Prandin	Xyzal
Claritin	Geodon	Pravastatin Sodium	Zaditor
Rx PA Appeals	0	0	
Rx PA Medical Reviews	1		
Inpatient Days	240,263	220,852	8.8%
ER visits	173,985	155,503	11.9%
Physician Visits	929,631	891,973	4.2%
Physicians w/25+ Patients	5,332	4,761	12.0%
Physicians w/50+ Patients	4,248	3,745	13.4%
Specialist Visits	6,700	6,810	-1.6%

SCR 54 TRACKING

SFY 2009 - Quarter 1 (July - September 2008)

Information Category	Current Quarter	Previous Year Quarter	Percent Change	
Eligibles	1,047,733	1,001,411	4.0%	
Recipients	998,642	920,734	8.5%	
Total Scripts Paid	2,343,132	2,184,657	7.2%	
Total Scripts Paid with PA	69,392	77,932	-11.0%	
Rx PA Requests Denied	3			
Medications				
Abilify	Claritin RediTabs	Grilulvin V Tablet	Prevacid Naprapac	Zanaflex
Ability Discreet	Claritin Syrup	Humatope	Prilosec	Zegerid
Accuneeb	Claritin Tab	Innoven XL	Proquin XR	Zofia
Accupril	Claritin-D 12 Hour	Iquix	Prosom	Zmax
Accuteric	Claritin-D 24 Hour	Itraconazole	Protonix	Zocor
Aciphex	Comtan	Kytril	Provigil	Zofran
Actiq	Corteg CR	Levquin	Prozac Weekly	Zofran ODT
Advicor	Crestor	Ubalda	Pulmicort	Zomig
Alamast	Cymbalta	Upofen	Pulmicort Flexhaler	Zomig ZMT
Allegra	Dalmane	Loprox Gel	Pulmicort Respules	Zytlo
Allegra ODT	Dantrolium	Loprox Shampoo	Pulmicort Turbuhaler	Zymar
Allegra-D 12 Hour	Dantrolene Sodium	Lovaza	Quinapril HCL	Zyprexa
Allegra-D 24 Hour	Darvon-N	Mavart	Quinapril Hydrochlorothiazide	Zyprexa Zydis
Alocril	Dextro	Mavart MLI	Quinaretic	Zytac
Alomide	Dextro LA	Mefenamic Acid	Quivin	Zytac Chew tabs
Atosiprev	Diltrorel	Montax	Ranidol	Zytac Syrup
Alupent	Ditropan XL	Metaproterenol Sulfate	Razadyno	Zytac-D
Ambien CR	Doral	Moxipril HCL	Razadyno ER	
Amergo	Duoneb	Moxipril Hydrochlorothiazide	Relpax	
Amrix	Duragesic	Monopril	Remicade	
Antara	Epogen	Monopril HCT	Rhinert Aquia	Total Drugs = 197
Anzemet	Ertaczo	Nasarel	Ritatin LA	
Aplidra	Estazolam	Nofazodone HCL	Somprex D	
Atria	Evista	Neo-Fradin	Simvastatin	
Atriflote 50	Evoliderm	Neomycin Sulfate	Skelaxin	
Atriflote 75	Exelon	Noflex	Soma	
Azmanex	Extina	Ormacor	Sonata	
Atacand	Factive	Omeprazole	Soperax	
Atacand HCT	Fazolo	Omnicet	Strattera	
Augmentin XR	Fenofibrate	Opans	Suprax	
Avanza	Fenoglide	Opans ER	Symbax	
Axert	Fentanyl	Optivar	Tarka	
Azaspire	Fentanyl Citrate	Orenda	Tekturna	
Bactroban	Fentora	Orphenadrine Citrate	Teveten	
Becconase AQ	Femid	Oxitrat	Ticla	
Blaxin XL	Ferotenidine HCL	Oxybutynin Chloride ER	Ticlopidine HCL	
Boniva	Flagyl ER	Oxycodeone HCL	Trigilde	
Brovana	Furazepam HCL	Oxycontin	Ultram ER	
Caduet	Folic Acid/Beta Blocker	Parlet DC	Uniretic	
Cetirizine HCL	Foradil	Pantoprazole Sodium	Unisacc	
Childrens Claritin	Forato	Paul CR	Viramyst	
Clovox	Fortical	Perlac	Vfend	
Clovox Oint	Foshospiril Sodium	Pentasa	Welchol	
Clovox Ointment	Foshospiril Hydrochlorothiazide	Perforomist	Wellbutrin XL	
Cipro HC	Forsenol	Pexeva	Xalatan	
Cipro Suspension	Frova	Ponstel	Xifaxan	
Cipro XR	Genotropin	Prandin	Kyval	
Claritin	Geodon	Pravastatin Sodium	Zaditor	
Rx PA Appeals	0	0		
Rx PA Medical Reviews	1			
Inpatient Days	215,506	213,013	1.2%	
ER visits	165,214	134,185	23.1%	
Physician Visits	623,349	797,259	3.3%	
Physicians w/25+ Patients	5,144	4,421	16.4%	
Physicians w/50+ Patients	4,046	3,367	20.2%	
Specialist Visits	6,515	6,232	4.5%	

SCR 54 TRACKING

SFY 2009 - Quarter 2 (October - December 2008)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligibles	1,096,999	1,048,177	4.7%
Recipients	995,441	952,665	4.6%
Total Scripts Paid	2,634,217	2,571,849	2.4%
Total Scripts Paid with PA	80,015	83,618	-4.3%
Rx PA Requests Denied	10	0	
Medications			
Ability	Clarinex Red Tabs	Gizelvin V Tablet	Prevacid Naprapac
Ability Discmelt	Claritin Syrup	Hurnatropo	Zanaflex
Accunob	Claritin Tabs	Innopran XL	Zegrid
Accupril	Clarinex D 12 Hour	Iquix	Zetia
Accuretic	Claritin D 24 Hour	Itraconazole	Zmax
Aches	Cortzan	Kytril	Zocor
Actiq	Coreg CR	Lovaquin	Zovigil
Advicer	Crestor	Ualda	Zofran ODT
Alamist	Cymbalta	Upofen	Pulmicort
Allegra	Dalmane	Loprox Gel	Pulmicort Flexhaler
Allegra ODT	Dantrolene	Loprox Shampoo	Pulmicort Respules
Allegra-D 12 Hour	Dantrolene Sodium	Lovaza	Pulmicort Turbuhaler
Allegra-D 24 Hour	Darvon N	Makart	Quinapril HCl
Alocril	Dextrof	Makart M/L	Quinapril Hydrochlorothiazide
Nomide	Dextrof LA	Mefenamic Acid	Quinaretic
Atoprev	Didronel	Mentax	Quixin
Alupent	Ditrepan XL	Metaproterenol Sulfate	Raniclor
Amblon CR	Doral	Moxepip HCl	Razadyme
Amerge	Duoneb	Moxepip-Hydrochlorothiazide	Razadyme ER
Amrix	Duragestic	Monopril	Relpax
Antara	Epopon	Monopril HCT	Remicade
Anzemet	Etracoz	Nasarel	Rhincon Aqua
Apidra	Estazolam	Nefazodone HCl	Ridin LA
Atutra	Evista	Noo Fradin	Semprex-D
Athrotec 50	Exoldorm	Neomycin Sulfate	Simvastatin
Athrotec 75	Exelon	Nordox	Skelaxin
Asmerex	Extina	Ormacor	Soma
Atacand	Factive	Omeprazole	Sondita
Atacand HCT	Fazacto	Omnicef	Sporanox
Augmentin XR	Fenofibrate	Opana	Shattera
Avanza	Fenoglide	Opana ER	Suprax
Avoret	Fentanyl	Opiivar	Symbyax
Azaste	Fentanyl Citrate	Orenzia	Taska
Bactroban	Fentora	Orphenadrine Citrate	Tekturna
Beconase AQ	Femid	Oxitat	Teveton
Bioxin XL	Fenoferolidine HCL	Oxybutynin Chloride ER	Ticlia
Boniva	Flagyl ER	Oxycodeone HCl	Ticlopidine HCl
Brovana	Flurazepam HCl	Oxycontin	Triglide
Caduet	Fluticasone Propionate	Panlor DC	Ulfran ER
Cetirizine HCL	Forast	Pantoprazole Sodium	Univasc
Childrens Clolin	Forteo	Paul CR	Viramyst
Clovan	Fortical	Pendac	VFEND
Clovan Oint	Fosinopril Sodium	Pentasa	Welchol
Clovan Ointment	Fosinopril Hydrochlorothiazide	Perforomist	Wellbutrin XL
Cipro HC	Forsenol	Pexeva	Xolatan
Cipro Suspension	Frova	Ponstel	Xanax
Cipro XR	Genotropin	Prandin	Xyzal
Clarinex	Geodon	Pravastatin Sodium	Zantac
Rx PA Appeals	0	0	
Rx PA Medical Reviews	0	0	
Inpatient Days	228,356	225,321	1.3%
ER visits	150,584	160,325	-6.1%
Physician Visits	955,234	887,568	7.6%
Physicians w/25+ Patients	4,796	4,548	5.5%
Physicians w/50+ Patients	3,694	3,466	6.6%
Specialist Visits	6,536	6,446	1.4%

SCR 54 TRACKING

SFY 2009 - Quarter 3 (January - March 2009)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>	
Eligibles	1,116,551	1,066,879	4.8%	
Recipients	1,012,418	963,008	5.1%	
Total Scripts Paid	2,827,636	2,660,427	6.3%	
Total Scripts Paid with PA	65,278	71,856	-21.0%	
Rx PA Requests Denied	9	0		
Medications				
Abelcet	Cipro HC	Fenofibrate	Ocuflox	Skelaxin
Ability Dismet	Cipro Suspension	Fenoglide	Oflloxacin	Soma
Accubed Low Dose	Cipro XR	Fentanyl Citrate	Olux E	Sonata
Aciphex	Ciprofloxacin ER	Formid	Olux-Olux E	Spectracet
Aclovate	Ciprofloxacin HCL	Flagyl ER	Omactar	Sparanox
Actiq	Clarithromycin	Flectot	Omepazole	Strattera
Advicor	Claritin Syrup	Flonase	Omnisat	Symbax
Albuterol Sulfate Low Dose	Claritin Tab	Flunisolide	Opana	Tarka
Alcologestine Dipropionate	Claritin-D 12 Hour	Benzepan HCl	Opromo ER	Tekluma
Allergro ODT	Claritin-D 24 Hour	Fluticasone Propionate	Orenzia	Ivator
Allergro D 12 Hour	Clarithromycin	Forteo	Orphenadrine Citrate	Teveten HCT
Allergro D 24 Hour	Clarithromycin ER	Fosamax	Ostifat	Tield
Alomide	Clobex	Fosamax Plus D	Oxybutynin Chloride ER	Ticloplante HCL
Athoprev	Cloderm	Fosinopril	Oxycodone HCL	Topicort
Ambien CR	Comtan	Frova	Oxycontin	Topicort LP
Armodinide	Cordran	Gentotropin	Pancrecarb MS-16	Triglide
Amerge	Coreg CR	Granisetron HCL	Pancrecarb MS-4	Ultram ER
Amelive	Crestor	Gruftin V Tablet	Pancrecarb MS-8	Unisect
Amix	Cromolyn Sodium	Halog	Panlor DC	Univasc
Androgel	Cutivate	Humatropo	Pantoprazole Sodium	Vancocin HCL
Antara	Gymnema	Innopran XL	Paracetamol HCL	Varos
Anzenemet	Dantrolene	Invega	Paxil CR	Vantin
Apidra	Dantrolene Sodium	Ipratropium-Abuterol	Perlacl	Venlafaxine HCL
Aktra	Darvon N	Itraconazole	Pentasa	Verdeso
Athrotect 50	Dermatop	Kytril	Perfomist	VFEND
Athrotect 75	Disonate	Lamisil Granules	Ponstel	Vusion
Armanox	Disosimotazone	Levaquin	Prandin	Welchol
Atacand	Dietrol	Lialda	Prednicarbate	Wellbutrin XL
Macand HCT	Didronel	Lindane	Prevacid Naprapac	Xanax
Avanza	Diflazasone Diacetato	Uptoren	Pilosec	Xyzal
Avvert	Dipentum	Loprex Shampoo	Pristiq	Zanaflex
Azaste	Diropren XL	Lovaza	Proquin XR	Zingerid
Azlect	Duoneb	Lumigan	Protonix	Zolia
Bactroban	Duragestic	Evozo CR	Provigil	Zomig
Becsonase AQ	Econazole Nitrate	Maxat	Prozac Weekly	Zomig ZM1
Blaxin	Effexor	Maxat MIT	Psorcon	Zovirax
Blaxin XL	Elion	Meclofenamate Sodium	Pulmicort	Zyflo CR
Brovana	Emsam	Mefenamic Acid	Pulmicort Respules	Zyprox
Budeprion XL	Epopen	Mentax	Quixin	Zyprox Zyds
Bupropion XL	Ertaczo	Moxipril HCL	Razadyne	Zytac
Bystolic	Estrazolam	Moxipril Hydrochlorothiazide	Razadyne ER	Zytec
Caduet	Evista	Mometasone Furoate	Remicade	Zytec (Legend)
Cardura XL	Exelderm	Nabumetone	Renvela	Zytec-D
Cetpodoxime Proxetil	Exelon	Nasarel	Rhinocort Aqua	Zytec-D (Legend)
Childrens Claritin	Exelon Patch	Nofazodone HCL	Ritalin LA	
Cleopirox	Extina	Nasimycin Sulfate	Sempax-D	
Clexan	Factive	Nortek	Seroquel XR	
Clozan Oint	Fazaclo	Noxafil	Serostrin	
Total Drugs = 236				
Rx PA Appeals	0	0		
Rx PA Medical Reviews	0	0		
Inpatient Days	238,532	224,745	6.1%	
ER visits	168,832	176,078	-4.1%	
Physician Visits	986,440	931,686	5.9%	
Physicians w/25+ Patients	4,917	4,538	8.4%	
Physicians w/50+ Patients	3,759	3,456	8.5%	
Specialist Visits	6,614	6,401	3.3%	

SCR 54 TRACKING

SFY 2009 - Quarter 4 (April - June 2009)

Information Category	Current Quarter	Previous Year Quarter	Percent Change	
Eligibles	1,118,700	1,078,622	3.7%	
Recipients	1,024,215	1,002,136	2.2%	
Total Scripts Paled	2,532,276	2,662,985	-4.9%	
Total Scripts Paled with PA	92,979	79,973	16.3%	
Rx PA Requests Denied	13	0		
Medications				
Ability	Calcium Acetate	Emadine	Etoprox Shampoo	Prandin
Ability Discreet	Cardizem LA	Enablex	Lofrel	Prednicarbate
Accutane	Cetipodoxime Proxetil	Epopogen	Lovaza	Prevacid/Napropac
Accutane Low Dose	Cetizine HCL	Erfaizo	Lumigan	Prevpac
Aciphex	Childrens Claritin	Estazolam	Luvsia	Prilosec
Aclavate	Ciclopirox	Evista	Luvox CR	Pristiq
Actonel with Calcium	Clozan	Exelderm	Mavart	Proquin XR
Advil	Clozan Dint	Exelon	Mavart MIT	Protonix
Alomast	Cenzia	Exelon Patch	Meclofenamate Sodium	Provigil
Altufentol Sulfate	Cipro	Faxina	Mentax	Prozac Weekly
Altufentol Sulfate Low Dose	Cipro HC	Factive	Moxipril HCL	Pulmicort
Alclometasone Dipropionate	Cipro Suspension	Fenofibrate	Moxipril Hydrochlorothiazide	Pulmicort Respules
Allergra	Cipro XR	Fenoglide	Mometasone Furoate	Pylex
Allergra ODT	Ciprofloxacin HCL	Fentanyl	Nabumetone	Quilen
Allergra Susp	Claritin Redibits	Fentanyl Citrate	Nasarel	Razadyne
Allergra-D 12 Hour	Claritin Syrup	Fentora	Neftazodone HCL	Remicade
Allergra-D 24 Hour	Claritin Tab	Femid	Nisoldpine	Renuva
Alomide	Claritin-D 12 Hour	Fenofenadine HCL	Noftor	Renuva XL
Alvesco	Claritin-D 24 Hour	Flagyl ER	Ocufoxa	Renuva XL
Amblon Cr	Clarithromycin	Flektor	Oflloxacin	Rhinocort Aqua
Amcinonide	Clarithromycin ER	Flonase	Olu-E	Ritalin LA
Amerge	Clobex	Flunisolide	Olux-Olu E	Roxaren
Amrinive	Clofend	Flurazepam HCL	Omacer	Saleze
Amrix	CNL 8	Fluticasone Propionate	Omepraazole	Sanctura
Androgel	Cordran	Forteo	Ornithias	Sanctura XR
Antara	Coreg CR	Fosamax	Opana	Sancuso
Anixmet	Covera HS	Fosamax Plus D	Opana ER	Semprex-D
Apexicon	Crestor	Frova	Orenzia	Sorquel XR
Apidra	Cromolyn Sodium	Gritulvin V	Orphenadrine Citrate	Skelaxin
Atrotra	Cultivate	Gritulvin V tablet	Orphenadrine Compound	Soma
Athrotec 50	Cymbalta	Halog	Orphenadrine Compound Forte	Sonata
Athrotec 75	Dantrolene	Humatope	Orphenegestol Forte	Spectacef
Axonex	Dantrolene Sodium	Imtirex	Oxitot	Sparanox
Afacaand	Darvon-N	Imtirex INJ	Oxybutynin Chloride ER	Strattera
Afacaand HCT	Dermatop	Imtirex injection	Oxycodeone HCL	Symbax
Avinga	Desonate	Imtirex Nasal Spray	Oxycontin	Tekturna
Axert	Doxazosine	Imtirex tablet	Pancarecarb MS-16	Topicort
Azaste	Doxazosine	Invega	Pancarecarb MS-4	Topicort LP
Beconase AQ	Dosokyn	Ipratropium Albuterol	Pancarecarb MS-8	Tracleer
Betaxolol HCL	Detrool	Itraconazole	Pancre DC	Irigide
Baxin	Didronel	Kytril	Pantoprazole Sodium	Ultram ER
Baxin XL	Diflunisal Disacetate	Lamisil Granules	Paroxetine HCL	Uniretic
Brevana	Ditropan XL	Levagrin	Paril CR	Univasc
Budopion XL	Duoneb	Lidac	Ponlac	Vanics
Budesonido	Duragesic	Lindane	Pontasa	Vantin
Bupropion XL	Econazole Nitrate	Uprofen	Poxtoromid	Venlafaxine HCL
Bystolic	Effexor	Lotra	Ponsol	Venlafaxine HCL ER
Caduet	Elphos	Loprox	Prandin	Verapamil ER
Rx PA Appeals	0	0		
Rx PA Medical Reviews	2	0		
Inpatient Days				
ER visits	235,000	240,263	-2.2%	
Physician Visits	168,998	173,985	-2.9%	
Physicians w/25+ Patients	941,042	929,631	1.2%	
Physicians w/50+ Patients	5,005	5,332	-6.1%	
Specialist Visits	3,872	4,248	-8.9%	
	6,659	6,700	-0.6%	

SCR 54 TRACKING

SFY 2010 - Quarter 1 (July - September 2009)

Information Category	Current Quarter	Previous Year Quarter	Percent Change	
Eligible Recipients	1,141,692	1,026,119	4.2%	
Total Scripts Paid	1,035,515	998,842	3.8%	
Total Scripts Paid with PA	2,660,767	2,343,132	13.6%	
Rx PA Requests Denied	96,026	69,392	38.4%	
Rx PA Requests Denied	11	0		
Medications				
Ability	Calcium Acetate	Emodine	Lopax Shampoo	Prandin
Ability Dismett	Cardizem LA	Enablex	Lotrel	Prednicarbate
Accunisub	Cefoperazone Proxel	Epopen	Lovaza	Prevacid Napropac
Accunisub Low Dose	Cetirizine HCL	Ertaczo	Lumigan	Prevpac
Aciphex	Childrens Claritin	Estradiol	Lunesta	Prilosec
Advocate	Clopirox	Evista	Luvix CR	Pristiq
Actonel with Calcium	Clozan	Evdem	Maxalt	Proquin XR
Advicer	Clozan Oint	Exelon	Maxalt M/T	Protonix
Alamast	Climzia	Exelon Patch	Medostenamate Sodium	Provigil
Albuterol Sulfate	Cipro	Extra	Mentax	Prozac Weekly
Albuterol Sulfate Low Dose	Cipro HC	Factive	Moexipril HCL	Pulmicort
Alclometasone Dipropionate	Cipro Suspension	Fenofibrate	Moexipril Hydrochlorothiazide	Pulmicort Respules
Allegra	Cipro XR	Foroglide	Mometasone Furoate	Pylora
Allegra ODT	Ciprofloxacin HCL	Fontanyl	Nabumetone	Quin
Allegra Sup	Clarimax Red tabs	Fontanyl Citrate	Nasarel	Razadine
Allegra-D 12 Hour	Clarimax Syrup	Fentora	Naftazodone HCL	Remicade
Allegra-D 24 Hour	Clarimax Tab	Fezmid	Nitoldipine	Renvela
Alomide	Clarimax-D 12 Hour	Flaxofendidine HCL	Noctis	Rixup XL
Alvesco	Clarimax-D 24 Hour	Flogit ER	Ocufo	Rhinocord Aqua
Ambien Cr	Clarithromycin	Flectot	Ofloxacin	Ritalin LA
Amcinonide	Clarithromycin ER	Flonase	Oluv E	Roxerem
Amerge	Clobes	Flunisolide	Olux-Olux E	Salzen
Amotive	Clobenz	Flurazepam HCL	Omacor	Sancutura
Amix	CNL 8	Fluticasone Propionate	Omeprazole	Sancutura XR
Androgel	Cordran	Forteo	Omrsas	Sancus
Antara	Corgi CR	Fosamax	Opanda	Semprev-D
Anxemet	Covera HS	Fosamax Plus D	Opanda ER	Seroquel XR
Apecon	Crétor	Frava	Orencia	Skelaxin
Asidra	Cromolyn Sodium	Gritvin V	Orphenadrine Citrate	Soma
Atifra	Cultivate	Gritvin V Tablet	Orphenadrine Compound	Sonata
Athrotec 50	Cymbalta	Halog	Orphenadrine Compound Forte	Spectacef
Athrotec 75	Dantrol	Humatropo	Ophengesic Forte	Sporanox
Atemex	Dantrolene Sodium	Imitrex	Oxitat	Strattera
Alcanid	Darvan N	Imitrex INJ	Oxybutynin Chloride ER	Symbax
Alcanid HCL	Desmoprop	Imitrex Injection	Oxycodeone HCL	Tekturna
Avinza	Desonete	Imitrex Nasal Spray	Oxycontin	Tektung HCL
Axert	Desoxymetasone	Imitrex Tablet	Pancarecarb MS-16	Topicort
Azaste	Desoxyn	Invega	Pancarecarb MS-4	Topicort IP
Beconase AQ	Dotrol	Ipratropium-Albuterol	Pancarecarb MS-8	Tracleor
Betaxolol HCL	Didronel	Itraconazole	Panfor DC	Trigida
Blavix	Diltiazene Diacetate	Kytril	Pantoprazole Sodium	Ultram ER
Blavix XL	Diltropan XL	Lamisil Granules	Paroxetine HCL	Uniretic
Brovana	Duoneb	Levaquin	Paul CR	Univasc
Budeprion XL	Duragesic	Udala	Pentac	Vanos
Budesonide	Econazole Nitrate	Undane	Pentasa	Vantin
Bupropion XL	Effexor	Uptoren	Potormist	Venlafaxine HCL
Bystolic	Elphos	Lofibra	Ponsol	Venlafaxine HCL ER
Caduet	Elocon	Loiprox	Prandin	Verapamil ER
Rx PA Appeals	0	0		
Rx PA Medical Reviews	0	0		
Inpatient Days	225,299	215,606	4.5%	
ER visits	172,538	165,214	4.4%	
Physician Visits	934,081	823,349	13.4%	
Physicians w/25+ Patients	5,029	5,164	-2.2%	
Physicians w/50+ Patients	3,884	4,036	-4.0%	
Specialist Visits	6,618	6,515	1.6%	

SCR 54 TRACKING

SFY 2010 - Quarter 2 (October - December 2009)

Information Category	Current Quarter	Previous Year Quarter	Percent Change		
Eligible Recipients	1,155,049	1,108,311	4.2%		
Total Scripts Paid	1,050,393	996,441	5.4%		
Total Scripts Paid with PA	2,789,047	2,634,217	5.9%		
Rx PA Requests Denied	118,814	80,015	48.5%		
Medications					
Abilify	Cadura XL	Duoneb	Itraconazole	Opana	Razorem
Ability Discomit	Cetidin	Dutezol	Kapidex	Opana ER	Saxzon
Accutane	Cetpodoxime-Proxetil	Econazole Nitrate	Kineret	Optivar	Sanctura
Accutab Low Dose	Celebrex	Effexor	Kytril	Oracea	Sanctura XR
Aciphex	Cessamet	Effexor XR	Lamist	Orconia	Sancuso
Actiq	Corizine HCL	Elostat	Lamist Granules	Orphenadrine Citrate	Semiprev D
Acular	Childrens Claritin	Elphos	Levagum	Orphenadrine Compound	Seroquel XR
Acular LS	Ciclosporix	Emend	Liata	Orphenadrine Compound Forte	Skelaxin
Advicor	Clozaril	Enablex	Lindane	Orphenegesic	Soma
Abuterol Sulfate	Clozaril Oint	Epogen	Uptone	Orphenegesic Forte	Sonata
Abuterol Sulfate Low Dose	Cirzia	Ertaczo	Locoid Lipocream	Oxitat	Spectracet
Allegra	Cipro	Estazolam	Loprox	Oxybutynin Chloride ER	Sporanox
Allegra CDT	Cipro Suspension	Etidronate Disodium	Lotrel	Oxycodone HCL	Strattera
Allegra Sup	Cipro XR	Evista	Lovaza	Oxycontin	Symbax
Allegra-D 12 Hour	Coprofloxacin ER	Exederm	Lumigan	Pancorestat MS-16	Tekturna
Allegra-D 24 Hour	Coprofloxacin HCL	Exelon	Bunesta	Pantol DC	Tekturna HCL
Alocril	Clofarcox	Extina	Luvox CR	Pantoprazole Sodium	Testim
Alopramide	Clarimax Syrup	Factive	Malathion	Paroxetine HCL	Teveten
Alvesco	Clomox Tab	Fenofibrate	Maxilar Autohaler	Patania	Teveten HCL
Ambien Cr	Claritin D 12 Hour	Fenoglide	Maxalt	Peril CR	Topical
Amberge	Claritin D 24 Hour	Fontanyl	Maxalt MII	Periac	Topicort LP
Amavive	Clarithromycin	Fentanyl Citrate	Mentax	Pentasa	Taviaz
Amphetamine Salt Combo	Clarithromycin ER	Fexmid	Metaproterenol Sulfate	Performist	Tracleer
Antara	Clobex	Fexofenadine HCL	Mirapex	Plexeva	Uloric
Anxiomet	Cloderm	Flagyl ER	Moxipril HCL	Prandinet	Ultrans Er
Apikra	Clozapine	Flecten	Moxipril Hydrochlorothiazide	Prandin	Ultraso
Apidra SoloStar	CNL 8	Flonase	Mometasone Furoate	Provacie	Ultraso MT 12
Aplenzin	Comtan	Flunisolide	Nabumetone	Priosec	Ultraso MT 18
Apriso	Cordran	Flurazepam HCL	Nasacort AQ	Pristiq	Ultraso MR 20
Arthrotec 50	Coreg CR	Fluticasone Propionate	Nefazodone HCL	Procentra	Uniretic
Arthrotec 75	Cromolyn Sodium	Forsteo	Novanac	Proquin XR	Univasc
Asmanee	Cutivate	Fortical	Nisoldipine	Protonik	Vanos
Atacand	Cymbalta	Fosamax	Norflex	Proventil HFA	Vanxin
Atacand HCT	Dantrolum	Fosamax Plus D	Noroxin	Provigil	Verlafaxine HCL
Athrevent	Dantrolene Sodium	Frova	Novolin 70-30	Prozac	Veromyst
Avanza	Darvan N	Gefitinib V	Novolin 70-30 Innolet	Prozac Weekly	Verapamil ER
Avert	Demeocycline HCL	Glisofulvin	Novolin N	Pulmicort	Verdeso
Azaste	Desonate	Halog	Novolin N Innolet	Pulmicort Flexhaler	Verolan PM
Azlect	Desoximetasone	Humatropo	Novolin R	Pylora	Voxol
Beconase AQ	Detro�	Hydrocortisone Butyrate	Novolog	Quixin	ViEND
Baxin	Dextroamphetamine-Amphetamine	Imtriox	Novolog Mix 70-30	Rapallo	Vusion
Baxin XL	Didronel	Imtriox Injection	Noraflo	Razadyne ER	Vytarin
Brevana	Diflunisal Disacetate	Imtriox Nasal Spray	Ocuflox	Romilade	Vyvanse
Budeprion XL	Diduradil 5	Imtriox Tablet	Oftloxacin	Ronvela	Welchol
Bucksone	Ditropan XL	Invega	Olux E	Ropcup XL	Wellbutrin XL
Bupropion XL	Dorzolamide HCL	Ipratropium Bromide	Omeprazole	Rhinocort Aqua	Xtrom
Calcium Acetate	Dorzolamide-Timolol	Ipratropium Atropitol	Omnaris	Risperdal Consta	Xtavan
Cardizem LA	Dronabinol	Iquix	Omniset	Ritalin LA	Xolegel
Rx PA Appeals	0	0			Xopenex HFA
Rx PA Medical Reviews	2				Xyzal
Inpatient Days					Zanaflex
ER visits	226,111	228,356	-1.0%		Zegerid
	180,322	150,584	19.7%		Zeta
Physician Visits	976,223	955,234	2.2%		Zmax
Physicians w/25+ Patients	5,166	4,796	7.7%		Zomig
Physicians w/50+ Patients	3,950	3,694	6.9%		Zomig ZMT
Specialist Visits	6,736	6,536	3.1%		Zovirax
					Zymar
					Zyprexa
					Zyprexa Zydis
					Zytrex
					Zytrex-D
					Total Drugs = 306

SCR 54 TRACKING

SFY 2010 - Quarter 3 (January - March 2010)

Information Category	Current Quarter	Previous Year Quarter	Percent Change		
Eligible Recipients	1,176,461	1,119,903	5.1%		
Total Scripts Paid	1,073,501	1,012,418	6.0%		
Total Scripts Paid with PA	2,915,784	2,627,636	3.1%		
Rx PA Requests Denied	122,650	66,278	48.2%		
Medications					
Abilify	Cefdinir	Effexor XR	Tocloid Ulocreream	Oxybutynin Chloride ER	Strattera
Ability Discomft	Celphadoxime Proxetil	Elestat	Lofibra	Oxycodone HCL	Symbax
Accutane	Celebrex	Elphos	Loprox	Oxycontin	Tekturna
Aciphex	Cetirizine HCL	Emond	Lottrel	Pancorecarb MS-16	Tekturna HCL
Actiq	Children's Claritin	Emsam	Lovaza	Pancorecarb MS-8	Tidim
Acular	Ciclopirox	Entek	Lumigan	Pantac DC	Ticlid
Acular LS	Clozar	Epogen	Lunesta	Pantoprazole Sodium	Ticlopidine HCL
Advicor	Cimzia	Ertaczo	Luxtor CR	Paracetamol HCL	Topicort
Albuterol Sulfate	Cipro	Etrazonam	Malathion	Patanase	Topicort LP
Allroga	Cipro HC	Evista	Maxair Autohaler	Paxil CR	Tavist
Allroga ODT	Cipro XR	Exederm	Maxat	Periac	Tracleer
Allroga D 12 Hour	Ciprofloxacin ER	Extina	Maxalt M/T	Pentasa	Iriglido
Allroga D 24 Hour	Ciprofloxacin HCL	Factive	Montax	Perforomist	Uloric
Aloril	Claritin	Fenofibrate	Melatoperenol Sulfate	Poxiva	Ultram ER
Alemdri	Claritin D 12 Hour	Fenoglide	Mropex	Pramipexole Dihydrochloride	Ultraso
Alvisco	Claritin D 24 Hour	Fentanyl	Moxiphi HCL	Prandimet	Ultraso MT 12
Ambien CR	Clarithromycin	Fontanly Citrate	Moxipril Hydrochlorothiazide	Prandin	Ultraso MT 18
Amerge	Clarithromycin ER	Fontora	Mycelex	Previpac	Ultraso MT 20
Amesive	Clobex	Flexmid	Nabumetone	Prilosec	Uniretic
Amix	Cloderm	Flexonadenine HCL	Nasacort AQ	Pristiq	Univasc
Ancebon	Gclozpine	Flexonadenine-PSE ER	Nasarel	Procentra	Vantin
Antara	Clozaril	Flagyl ER	Nefazodone HCL	Protonix	Venlafaxine HCL
Antozmet	Cordran	Flectot	Nevanac	Provigil	Veramyst
Apexicon	Coreg CR	Flonotide	Nisoldipine	Prazac Weekly	Verapamil ER
Aprilia	Crolem	Flurazepam HCL	Nortri	Pumicort	Verdeso
Aprinda SoloStar	Cromolyn Sodium	Fluticasone Propionate	Noxatin	Pumicord Flexhaler	Verol
Aplenzin	Cymbalta	Forteo	Novolin 70 30	Pyleta	VEEND
Apriso	Dalmane	Fortical	Novolin 70 30 Innolet	Quilon	Vusion
Arthrotec 50	Dantrolene	Fosamax	Novolin N	Rapallo	Vytarin
Arthrotec 75	Dantrolene Sodium	Fosamax Plus D	Novolin N Innolet	Razadyne	welchol
Asmanex	Darvon N	Frova	Novolin R	Razadyne ER	Wellbutrin XL
Atacand	Declomycin	Galantamine HBR	Novolog	Remicade	Xbrom
Atacand HCT	Demeclocycline HCL	Gitufuvir V	Novolog Mix 70 30	Renvela	Xanax
Atrovent	Desonate	Halog	Noxafil	Rexup XL	Xolegel
Avinza	Desoximetasone	Humatropo	Ocuflax	Rhinocort Aquia	Xopenex HFA
Axert	Dextrol	Imtrex	Otiotakin	Risperdal Consta	Xyzal
Azalte	Dextroamphetamine Amphetamine	Invega	Olux-Olux E	Ritalin LA	Zanaflex
Azlect	Didronel	Ipratropium Bromide	Omepazole	Rizerem	Zeta
Baclofen AQ	Dilazepate Diacetate	Ipratropium-Abuterol	Omnires	Solifen	Zmax
Betaxolol HCL	Dialaudid-S	Itraconazole	Omnicef	Sanctura	Zmax Pediatric
Bixin	Diltropan XL	Kapildex	Opana	Sanctura XR	Zomig
Bixin XL	Dorzolamide HCL	Kinet	Opana ER	Sancuso	Zomig ZMT
Brovana	Dorzolamide-Timolol	Kytril	Optivar	Somprex-D	Zovirax
Budeprion XL	Dronabinol	Lomist	Oracea	Skelaten	Zymar
Bucksonide	Duronob	Levaquin	Orphenadrine Citrate	Soma	Zyprexa
Bupropion XL	Durazol	Liada	Orphenadrine Compound Forte	Sonata	Zyprexa Zydis
Calcium Acetate	Econazole Nitrate	Lindane	Orphenadrine Forte	Sporanox	Zytec
Cardizem LA	Effexor	Utopicen	Total Drugs = 289		
Rx PA Appeals	0	0			
Rx PA Medical Reviews	0	0			
Inpatient Days	240,808	238,532	1.0%		
ER visits	174,173	168,832	3.2%		
Physician Visits	982,590	986,440	-0.4%		
Physicians w/25+ Patients	5,338	4,917	8.6%		
Physicians w/50+ Patients	4,127	3,759	9.8%		
Specialist Visits	6,857	6,614	3.7%		

SCR 54 TRACKING

SFY 2010 - Quarter 4 (April - June 2010)

Information Category	Current Quarter	Previous Year Quarter	Percent Change		
Eligibles	1,189,493	1,135,208	4.6%		
Recipients	1,097,260	1,024,215	7.1%		
Total Scripts Paid	2,709,744	2,532,276	7.0%		
Total Scripts Paid with PA	133,873	92,979	44.0%		
Rx PA Requests Denied	6	0			
Medications					
Abilify	Bofexadol HCl	Dextilant	Halog	Olux-E	Saphis
Ability Discreet	Blair	Dextroamphetamine-Amphetamine Humatropo	Omeprazole	Sempred D	
Acbumet	Blaxin XL	Diltiazene Diacetate	Omnaris	Serodin	
Acon	Bromocriptine Mesylate	Dilaudid 5	Oninef	Simponi	
Aciphex	Brovana	Ditropan XL	Invega	Opana	Skeleaxin
Actonel w/ Calcium	Budeprion XL	Doxazosin HCl	Invega Sustenna	Opana ER	Skeleaxin
Acular	Budesonide	Dorazolamide-Timolol	Iproterium-Atropine	Optivar	Soma
Acular LS	Buproprion XL	Dronabinol	Iquix	Oracea	Sporanox
Acuvail	Caduet	Duromet	Itraconazole	Orphenadrine Citrate	Starlix
Adalat	Calcium Acetate	Duragics	Kapidex	Orphenadrine Compound	Strattera
Advisor	Cardene SR	Durezol	Kineret	Orphenadrine Compound Forte	Sular
Atorvastatin Sustato	Cardizem LA	Dynacirc CR	Kytril	Oxybutynin Chloride ER	Sumatriptan
Alegra	Cetidrin	Econazole Nitrate	Lamisil	Oxycodone HCl	Sumatriptan Succinate
Alegra ODT	Cetipodoxime Proxetas	Edular	Levosporazole	Oxycontin	Symbax
Alegra D 12 Hour	Celebrex	Efferex	Levoquin	Oxytrol	Tekturna
Alegra D 24 Hour	Cetorex	Efferex XR	Lidka	Pancarecarb MS-16	Tekturna HCT
Alocril	Childrens Claritin	Effient	Lindane	Pancarecarb MS-4	Testim
Alomide	Clozapine	Elestat	Lopecen	Pancarecarb MS-8	Ticlid
Altobac	Clozan	Elphos	Loftora	Pantoprazole Sodium	Ticlopidine HCl
Altopen	Cimzia	Embend	Loprox	Paroxetine HCl	Topical
Alvesco	Cipro	Emend	Lovaza	Patane	Topical IP
Ambien CR	Cipro HC	Epogen	Lumigan	Paril CR	Triglide
Amerge	Ciprofloxacin ER	Ertaczo	Lunesta	Pedaderm HC	Twynsta
Amesivive	Ciprofloxacin HCl	Estazolam	Luxor CR	Pegnitron	Tyasa
Amrix	Claritin	Evia	Malathion	Pegnitron Redipen	Uloxic
Anzemet	Clarinet D 12 Hour	Eveliderm	Makor Autohaler	Pentac	Ultram ER
Apexicon	Clarinet D 24 Hour	Extra	Montal	Pentasa	Ultrase
Apidra	Clarithromycin	Factive	Metaprenanol Sulitate	Performist	Ultrase MT 12
Apidra Solostar	Clarithromycin ER	Fencitabrate	Metaxalone	Perindopril Erbumine	Ultrase MT 20
Aplenzin	Clobex	Fenoglide	Mirapei	Pexeva	Uniretic
Apriso	Cloderm	Fentanyl Citrate	Mocipril-Hydrochlorothiazide	Pramipexole Hydrochloride	Univasc
Arthrotec 50	Clotrimazole	Fentora	Mycobex	Prevacid	Vanos
Arthrotec 75	Clozapine	Fexmid	Nabumetone	Prevac	Vanthin
Asmanex	Clozaril	Fexofenadine HCl	Nasocort AQ	Prilosec	Verlafaxine HCL
Atacand	CNI 8	Fexofenadine PSE-ER	Nateglinide	Pristiq	Verlafaxine HCLER
Atacand HCT	Colcrys	Flagyl ER	Nefazodone HCl	Procentra	Veramyst
Atravent	Comtan	Flecten	Novanac	Protonik	Verapamil ER
Avadale	Cordran	Flonase	Novum	Protonik IV	Vordin
Avapro	Corg CR	Flunisolide	Nipoldipine	Provant HFA	Vorinol PM
Avanea	Cromolyn Sodium	Furazepam HCl	Nortek	Provigil	Voxol
Avodart	Cymista	Fulicavone Propionate	Novolin 70-30	Prazac Weekly	VIEND
Avert	Dalmane	Fetteo	Novolin N	Puzmicit	Vusori
Azastro	Dantrolene	Fotical	Novolin R	Pulmicort Flexhaler	Vytorn
Azlect	Dantrolene Sodium	Fosamax	Novolog	Quin	Welchol
Bactroban	Darvon N	Fosamax Plus D	Novolog Mx 70-30	Rapato	Wenbutrin XL
Becanase AQ	Demeclocycline HCl	Frova	Novatil	Relpax	Xibrom
Benicar	Desonate	Glanfamine HBR	Nucynta	Remicade	Xitanan
Benicar HCT	Desoximetasone	Glenique	Numig	Renevia	Xolegal
Boprave	Detrol	Granisetron HCl	Ocuflox	Roquip XL	Xopenex HFA
Bosivance	Detrol LA	Gritfulin V	Oflazocin	Rhinocort Aqua	Zydr
Rx PA Appeals	0	0		Risperdal Consta	Zamicet
Rx PA Medical Reviews	0	0		Ritalin LA	Zanaflex
Inpatient Days	220,478	235,000	-6.2%	Roxetrem	Zetia
ER visits	170,985	166,998	1.2%	Ryzol	Zipsor
Physician Visits	937,305	941,042	-0.4%	Sazen	Zmax
Physicians w/26+ Patients	6,641	5,006	16.7%	Sanctura	Zmax Pediatric
Physicians w/50+ Patients	4,626	3,872	19.5%	Sanctura XR	Zomig
Specialist Visits	7,260	6,659	9.0%	Sancuso	Zomig ZMT
Total Drugs = 322				Zovirax	
				Zylo CR	
				Zymar	
				Zyptrex	
				Zyptrex Zydis	

SCR 54 TRACKING

SFY 2011 - Quarter 1 (July - September 2010)

Information Category	Current Quarter	Previous Year Quarter	Percent Change		
Eligible Recipients	1,209,429	1,157,861	4.5%		
Total Scripts Paid	1,115,609	1,036,515	7.2%		
Total Scripts Paid with PA	2,706,763	2,660,767	1.7%		
Rx PA Requests Denied	68,362	51,854	31.8%		
Medications					
Abilify	Bromocriptine Mesyate	Dorozolamide HCL	Invaga	Opana ER	Sophis
Ability Discreet	Brovana	Dorozolamide-Timolol	Invega Sustenna	Optivar	Sempred D
Accutane	Budesonide XL	Dronabinol	Ipratropium Bromide	Gracea	Simpsoni
Acon	Budesonide	Duoden	Ipratropium-Atropitol	Orphenadrine Citrate	Skeltaxin
Aciphex	Buproprion XL	Duragasic	Itraconazole	Orphenadrine Compound	Soma
Actonel w/ Calcium	Caduet	Durezol	Kapidex	Orphenadrine Compound Forte	Sporanox
Acular	Calcium Acetate	Dynaciac CR	Kineret	Oxybutyn Chloride ER	Statix
Acular LS	Cardizem LA	Econazole Nitrate	Kytril	Oxicodone HCL	Strattera
Actavis	Cardizem EA	Edular	Lamisil	Oxycontin	Sular
Adcirca	Cetipodoxime Proxetil	Efexor	Lansoprazole	Oxytrol	Sumatriptan
Advair	Celecoxib	Efexor XR	Levaquin	Pantoprazole Sodium	Sumatriptan Succinate
Albuterol Sulfate	Cetrotide	Effient	Lidda	Parlodol	Symbax
Allegra	Childrens Claritin	Elestat	Lindane	Paroxetine HCL	Tekturna
Allegra ODT	Clecloridix	Elphos	Upafen	Patanase	Tekturna HCl
Allegra-D 12 Hour	Clozan	Embeda	Locoid Lipocream	Peri CR	Testen
Allegra-D 24 Hour	Cimzia	Emond	Toprax	Pedialtern HC	Triclopidine HCL
Alli	Cipro	Erksam	Topaza	Pegnitron	Topictort
Allodox	Cipro HC	Eposen	Tumigan	Pegnitron Redpink	Topictort IP
Altopen	Ciprofloxacin ER	Ertaczo	Unesta	Pentac	Triglide
Alvesco	Ciprofloxacin HCL	Estazolam	Uvax CR	Pentasa	Twinsta
Amblion CR	Clarithex	Evista	Malathion	Perforomist	Tyros
Amergen	Claritin-D 12 Hour	Erelizium	Mazax Atabider	Perindopril Erbumine	Uloxic
Amesivive	Claritin-D 24 Hour	Exista	Mental	Pereva	Utram ER
Amix	Clarithromycin	Factive	Metaproterenol Sulfate	Pramipexole Dihydrochloride	Uniretic
Anzemet	Clarithromycin ER	Fenofibrate	Metaxalone	Prevacid	Univasc
Apidra	Clober	Fenofibrate Acid	Miraper	Prevpac	Vanos
Apidra SoloStar	Cloderm	Fenoglide	Moxisipril-Hydrochlorothiazide	Priosec	Vantin
Aplenzin	Clotrimazole	Fentanyl Citrate	Nabumetone	Priftiq	Verlafaxine HCL
Apriso	Clorazepine	Femid	Nasacert AQ	Procontra	Veramyst
Athrotec 50	Clozaril	Florotenadine HCL	Nateglinide	Protonix	Verapamil ER
Athrotec 75	CNL 8	Florotenadine-PSE-ER	Nefazodone HCL	Provential HFA	Vordeso
Astmanex	Colorys	Flagyl ER	Nevanac	Provigil	Verolan PM
Atacand	Coraton	Flectot	Neuum	Prozac Weekly	Vexol
Atacand HCT	Corg CR	Flonge	Nipoldipine	Pulmicort	VFEND
Atrovent	Cromolyn Sodium	Flunisolide	Novolin 70-30	Pulmicort Respules	Vusion
Avade	Cymbalta	Flurazepam HCL	Novolin N	Quelin	Vytarin
Avapro	Dantrolene	Fulicasone Propionate	Novolin R	Rapato	Welchol
Avinsa	Dantrolene Sodium	Forteo	Novolog	Reparax	Weltbutrin XL
Avodart	Demeclocycline HCL	Fortical	Novolog Mix 70-30	Remicade	Xiberm
Axert	Desonate	Fosamax	Novatil	Renuvia	Xitanan
Azastat	Desoximetasone	Fosamax Plus D	Nucynta	Requip XL	Xolegal
Azect	Desoxyn	Frova	Nuvigil	Rhinocort Aqua	Xopenex HFA
Bactroban	Detro	Glanamine HBR	Ocufoxa	Risperdal Consta	Xyzal
Beconase AQ	Detrol LA	Glenique	Ofoxacin	Ritalin LA	Zamicot
Benicar	Dexlant	Gransetron HCL	Olux E	Rozerem	Zanaflex
Benicar HCT	Dextroamphetamine-Amphetamine	Giltulvin V	Olux-Olux-E	Ryzolt	Zolia
Beprive	Disionet	Halog	Omnaris	Saxen	Zipsor
Belsivance	Difloracone Diacetate	Humatropo	Omnicef	Sanctura	Zmax
Baxin	Dilauidid S	Ibudone	Omnitropo	Sanctura XR	Zomig
Baxin XL	Ditropan XL	Intergen	Opana	Sancusa	Zomig ZM
Rx PA Appeals	0	0		Zovirax	
Rx PA Medical Reviews	0	0		Zylo CR	
Inpatient Days	215,341	225,299		Zymar	
ER visits	164,397	172,538	-4.4%	Zyprexa	
Physician Visits	890,240	934,081	-4.7%	Zyprexa Zwick	
Physicians w/25+ Patients	6,116	5,029	21.6%		Total Drugs = 308
Physicians w/50+ Patients	4,995	3,884	28.6%		
Specialist Visits	7,084	6,618	7.0%		

SCR 54 TRACKING

SEY 2011 - Quarter 2 (October - December 2010)

Information Category	Current Quarter	Previous Year Quarter	Percent Change		
Eligible Recipients	1,214,408	1,181,683	2.8%		
Total Scripts Paid	1,130,979	1,050,393	7.7%		
Total Scripts Paid with PA	3,113,201	2,789,047	11.6%		
Rx PA Requests Denied	172,066	118,814	44.8%		
Rx PA Requests Denied	27	0			
Medications					
Abilify	Botaxolol HCl	Dexilant	Halog	Oltux E	Sophris
Ability Discomit	Blaxin	Dextroamphetamine-Amphetamine/Humatrepte	Ibudene	Omeprazole	Semprex-D
Accutane	Blaxin XL	Diltiazem Disacetate	Invega	Orinase	Soratim
Aconin	Bromocriptine Mesylate	Dlazide 5	Invega Sustenna	Omnicef	Simponi
Aciphex	Brovana	Ditepan XL	Ipratropium-Albuterol	Opanga	Skelaxin
Actonel w/ Calcium	Budeprion XL	Dorezolamide HCl	Iquix	Opanga ER	Skelaxen
Acular	Budesonide	Dorezolamide-Timolol	Itraconazole	Optiva	Soma
Acular LS	Buproprion XL	Dronabinol	Itraconazole	Oracea	Sporanox
Acuvail	Caduet	Duoneb	Kapidex	Orphenadrine Citrate	Starlix
Adderall	Calcium Acetate	Durogesic	Kineret	Orphenadrine Compound	Strattera
Advair	Cardene SR	Durezol	Kytril	Orphenadrine Compound Forte	Sular
Abtuberol Sulfate	Cardzem LA	Dynaciac CR	Lansil	Oxybutynin Chloride ER	Sumatriptan
Allergia	Cefdinir	Econazole Nitrate	Lansoprazole	Oxycodone HCl	Sumatriptan Succinate
Alleria ODT	Cetipodoxime Proxetil	Edular	Levaquin	Oxycontin	Symbax
Alleria D 12 Hour	Celebrex	Effexor	Lialda	Oxytrol	Tekturna
Alleria D 24 Hour	Cetiraxol	Effexor XR	Lindane	Pancrecarb MS-16	Tekturna HCT
Alloctil	Childrens Clarinex	Effient	Utopicen	Pancrecarb MS-4	Testim
Alomide	Ciclopirox	Elestat	Locoid Liposcream	Pancrecarb MS-8	Ticlid
Altabix	Cloxin	Elphos	Lottbra	Pantoprazole Sodium	Ticlopidine HCl
Altopen	Cinzia	Emenda	Toprax	Paracetamol HCl	Topicort
Alvesco	Cipro	Ermet	Tovaza	Patane	Topicort LP
Ambien CR	Cipro HC	Epopien	Lumigan	Paix CR	Triglide
Amerge	Ciprofloxacin ER	Erfaco	Lunesta	Pedalderm HC	Tyrista
Amovive	Ciprofloxacin HCl	Etrazolam	Luxor CR	Peglitron	Tyrosa
Amrix	Claritin	Evista	Malathion	Peglitron Red pen	Uloxic
Anzenemet	Claritin D 12 Hour	Exelderm	Maxair Autohaler	Penlac	Ultram ER
Aperion	Claritin D 24 Hour	Exina	Mentax	Pentasa	Ultrase
Apidra	Clarithromycin	Factive	Metaproterenol Sulfate	Perforomist	Utrase MF 12
Apidra SoloSTAR	Clarithromycin ER	Fenofibrate	Metaxalone	Perindopril Erbumine	Utrase MF 20
Aplerenz	Clobex	Fenoglide	Miraper	Pexeva	Uniretic
Apriso	Cloderm	Fentanyl Citrate	Moxeipril Hydrochlorothiazide	Pramipexole Dihydrochloride	Univasc
Arthrotec 50	Clotrimazole	Fentora	Mycetex	Prevacid	Vanos
Arthrotec 75	Clozapine	Feumid	Nabumetone	PriLOSEC	Vantini
Armonox	Clozaril	Fexofenadine HCl	Nasacort AQ	Prisliga	Vericardine HCl
Atacand	CNL 8	Fexofenadine-PSE-ER	Nateglinide	Procentra	Verkaferline HCLER
Atacand HCT	Colorys	Flagyl ER	Nifazadone HCl	Protonix	Veramyst
Atrovent	Conton	Flectot	Nevanac	Protonix IV	Verapamil ER
Avadice	Cordian	Ronase	Nexium	Provant HFA	Verdeso
Avapro	Coret CR	Rinsolida	Nisoldipine	Provigil	Verelan PM
Avanza	Cromolyn Sodium	Flurazepam HCl	Norflex	Prazac	Vexol
Avodart	Cymbeta	Folic acid Propionate	Novolin 70-30	Pulmicort	VTEND
Aver	Dalmane	Torfeo	Novolin N	Pulmicort Flexhaler	Vusion
Azaste	Dantrolene	Fortical	Novolin R	Quinil	Vytorn
Azlect	Dantrolene Sodium	Fosamax	Novolog	Rapatio	Welchol
Bactroban	Darvon-N	Fosamax Plus D	Novolog Mix 70-30	Relpax	Wolbutrin XL
Beciclatine AQ	Demeclocycline HCl	Frova	Novatil	Remicade	Xibrom
Benicat	Desonate	Glanzamino HBR	Nucynta	Renevia	Xitanan
Benicat HCT	Desoximetasone	Glonique	Nuvigil	Requip XL	Xolegal
Bepreve	Detroit	Granisetron HCl	Ocuflax	Risperidol Aquia	Xopenex HFA
Besivance	Detroit LA	Gritfulin V	Otixazin	Risperidol Consta	Zyal
Rx PA Appeals	0	0		Riton LA	Zanicef
Rx PA Medical Reviews	0	0		Roxeter	Zanaflex
Inpatient Days	223,835	226,111	-1.0%	Zeta	Zeta
ER visits	180,840	180,322	0.3%	Ryzolt	Zipsor
Physician Visits	976,272	976,223	0.0%	Salzen	Zmax
Physicians w/25+ Patients	5,970	5,166	15.6%	Sanctura	Zmax Pediatric
Physicians w/50+ Patients	4,764	3,950	20.6%	Sanctura XR	Zomig
Specialist Visits	7,140	6,736	6.0%	Sancuso	Zomig ZMT
				Zovirax	Zovirax
				Zylie CR	Zylie CR
				Zymar	Zymar
				Zyprexa	Zyprexa
				Zyprexa Zydis	Zyprexa Zydis
				Total Drugs = 322	